STICH: Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease

• Sponsor: Duke University (Other)
• Overall Status: Completed
• CT.gov ID: NCT00023595
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI) (NIH)
• Enrollment: 2,136
• Location: 1
• Arms: 4
• Duration (Months): 166
• Patients Per Site Per Month: 12.9

Study Details

Study Description

Brief Summary

This study will compare medical therapy with coronary bypass surgery and/or surgical ventricular reconstruction for patients with congestive heart failure and coronary artery disease (CAD).

Condition or Disease	Intervention/Treatment	Phase
Cardiovascular Diseases; Coronary Disease; Heart Failure, Congestive; Heart Diseases	Procedure: CABG surgery plus MED; Drug: Active Medication Alone; Procedure: CABG plus MED and SVR	Phase 3

Detailed Description

BACKGROUND:

Congestive heart failure afflicts approximately five million Americans and is the leading cause of hospitalization in Americans over the age of 65. Most cases of congestive heart failure are due to CAD. Surprisingly little is known about the relative benefits of medical versus surgical therapy for patients with obstructive coronary disease and congestive heart failure. Randomized studies of medical therapy versus bypass surgery for obstructive coronary disease were conducted in the 1970s and did not include the systematic use of aspirin, arterial conduits, or lipid-lowering medications. In addition, patients with ejection fractions below 35% were specifically excluded from the three large randomized studies of medical therapy versus bypass surgery. While observational data from the 1970s and early 1980s suggest a survival advantage associated with bypass surgery in patients with low ejection fraction and congestive heart failure, biases favoring the referral of the fittest of such patients for bypass surgery may have confounded these comparisons. In addition, medical therapy for congestive heart failure has improved dramatically over the past two decades. Thus, the choice of medical therapy versus bypass surgery for patients with congestive heart failure and obstructive coronary disease is usually decided by guesswork. This study is designed to provide a solid answer.

PURPOSE:

STICH is a multicenter, international, randomized trial that addresses two specific primary hypotheses in patients with clinical heart failure (HF) and left ventricular (LV) dysfunction who have coronary artery disease amenable to surgical revascularization.

The first hypothesis is that restoration of blood flow by means of coronary revascularization recovers chronic LV dysfunction and improves survival, as compared to intensive medical therapy alone. The second hypothesis is that surgical ventricular restoration (SVR) to a more normal LV size improves survival free of subsequent hospitalization for cardiac cause compared to CABG alone.

Patients eligible for either medical therapy or CABG, but not eligible for the SVR procedure (Stratum A), will be randomized in equal proportions to medical therapy alone versus CABG plus medical therapy. Patients eligible for all three therapies (Stratum B) will be randomized in equal proportions to medical therapy alone, CABG plus medical therapy, and CABG plus SVR plus medical therapy. Patients whose severity of angina or CAD makes them inappropriate for medical therapy alone (Stratum C) will be randomized in equal proportions to CABG plus medical therapy versus CABG plus SVR plus medical therapy.

The overall target was to recruit 1200 patients into Hypothesis One and 1,000 patients into Hypothesis Two. Secondary endpoints include the role of myocardial viability, morbidity, economics, and quality of life. Core laboratories for quality of life/economics, cardiac magnetic resonance (CMR), echocardiography (ECHO), neurohormonal/cytokine/genetic (NCG), and radionuclide (RN) studies ensure consistent testing practices and standardization of data necessary to identify eligible patients and to address specific questions related to the stated hypotheses.

IMPORTANCE OF RESEARCH:

The most common cause of HF is no longer hypertension or valvular heart disease as it was in previous decades, but rather CAD. HF is a common worldwide disease and CAD is a frequent cause of HF initiation and progression. HF is responsible for approximately 1 million hospitalizations and 300,000 fatalities annually. The prevalence of HF is increasing, largely due to enhanced survival following acute myocardial infarction and other manifestations of CAD. No randomized trial has ever compared directly the long-term benefits of surgical, medical, or combined surgical and medical treatment of patients with ischemic HF. The STICH trial is the first trial to compare the long term benefits of surgical and medical treatment in patients with ischemic HF. Although modern medical therapy for HF modestly improves quality of life, a more aggressive approach with the surgical therapies being studied in the STICH trial may produce even greater improvements. The common clinical practice of not offering CABG to patients with LV dysfunction in regions found to be nonviable on noninvasive studies is not evidence-based. Since only those patients for whom intensive medical therapy is the only reasonable therapeutic alternative are excluded from this study, the results of the STICH trial should be applicable to most patients with CAD, HF, and systolic LV dysfunction. The results of the STICH trial will also establish whether measurements of neurohormonal and cytokine levels and genetic profiling are useful for directing patient management decisions, for monitoring the effectiveness of therapy, and for refining the optimal approach for selecting the treatment strategy most likely to be effective for the many of these patients.

Study Design

• Study Type: Interventional
• Actual Enrollment: 2136 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Surgical Treatment for Ischemic Heart Failure (STICH)
• Study Start Date: Jan 1, 2002
• Actual Primary Completion Date: Nov 1, 2015
• Actual Study Completion Date: Nov 1, 2015

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: H01: Medication Medical therapy alone to treat Coronary Artery Disease	Drug: Active Medication Alone; Standard medication for coronary artery disease and heart failure management.; Other Names: Standard medications for management of CAD and heart failure
Active Comparator: H01: Medication + CABG Coronary artery bypass graft surgery (CABG) plus Medication to treat coronary artery disease	Procedure: CABG surgery plus MED; CABG plus standard medication management for Coronary Artery Disease
Active Comparator: H02: Medication+CABG Coronary artery bypass graft surgery (CABG) plus Medication to treat coronary artery disease	Procedure: CABG surgery plus MED; CABG plus standard medication management for Coronary Artery Disease
Active Comparator: H02: Medication+CABG+SVR CABG plus Medication and Surgical ventricular reconstruction (SVR)	Procedure: CABG plus MED and SVR; H02: the experimental arm receives active medical therapy and CABG and surgical ventricular restoration whereas the control group receives active medical therapy and CABG; for H01: the experimental arm receives active medical therapy and CABG whereas the control group receives active medical therapy alone

Outcome Measures

Primary Outcome Measures

1. H01: All Cause Mortality [5 years post randomization]

2. H01: All Cause Mortality [10 years post randomization]

3. H02: All-cause Mortality or Cardiovascular Hospitalization [5 years post randomization]

Secondary Outcome Measures

1. H01: Cardiovascular Mortality (Defined as Sudden Death or Death Attributed to Recurrent MI, HF, a Cardiovascular Procedure, Stroke, or Other Cardiovascular Etiology). [10 years post randomization]

2. H01: Cardiovascular Mortality (Defined as Sudden Death or Death Attributed to Recurrent MI, HF, a Cardiovascular Procedure, Stroke, or Other Cardiovascular Etiology). [5 years post randomization]

3. H01: Mortality or Cardiovascular Hospitalization [up to 5 years post randomization]

4. H01: Mortality or Cardiovascular Hospitalization [up to 10 years post randomization]

5. H02: All-cause Mortality [up to 5 years]

6. H01: All-cause Mortality Within 30 Days After Randomization [30 days post randomization]

7. H02: All-cause Mortality Within 30 Days After Randomization [30 days post randomization]

8. H01: All-cause Mortality or Heart-failure Hospitalization [5 years post randomization]

9. H02: All-cause Mortality or Heart-failure Hospitalization [5 years post randomization]

10. H01: All-cause Mortality or Heart-failure Hospitalization [10 years post randomization]

11. H01: Heart Failure Hospitalization [5 years post randomization]

12. H02: Heart Failure Hospitalization [5 years post randomization]

13. H01: Heart Failure Hospitalization [10 years post randomization]

14. H01: Cardiac Procedure: Heart Transplant [5 years post randomization]

15. H02: Cardiac Procedure: Heart Transplant [5 years post randomization]

16. H01: Cardiac Procedure: Heart Transplant [10 years post randomization]

17. H01: Cardiac Procedure: Left Ventricular Assist Device (LVAD) [5 years post randomization]

18. H02: Cardiac Procedure: Left Ventricular Assist Device (LVAD) [5 years post randomization]

19. H01: Cardiac Procedure: Left Ventricular Assist Device (LVAD) [10 years post randomization]

20. H01: Cardiac Procedure: Implantable Cardioverter Defibrillator (ICD) [5 years post randomization]

21. H02: Cardiac Procedure: Implantable Cardioverter Defibrillator (ICD) [5 years post randomization]

22. H01: Cardiac Procedure: Implantable Cardioverter Defibrillator (ICD) [10 years post randomization]

23. H01: Stroke [5 years post randomization]

24. H01: Stroke [10 years post randomization]

25. H02: Stroke [5 years post randomization]

26. H01: All-cause Mortality or Revascularization (CABG or PCI) [5 years post randomization]

    CABG = coronary artery bypass grafting. For patients randomized to CABG or CABG +SVR group, this represents the repeat CABG received during follow-up. PCI = Percutaneous Coronary Intervention.

27. H02: All-cause Mortality or Revascularization (CABG or PCI) [5 years post randomization]

    CABG = coronary artery bypass grafting. For patients randomized to CABG or CABG +SVR group, this represents the repeat CABG received during follow-up. PCI = Percutaneous Coronary Intervention.

28. H01: All-cause Mortality or Revascularization (CABG or PCI) [10 years post randomization]

    CABG = coronary artery bypass grafting. For patients randomized to CABG or CABG +SVR group, this represents the repeat CABG received during follow-up. PCI = Percutaneous Coronary Intervention.

29. H01: All-cause Mortality, Heart Transplant or LVAD [5 years post randomization]

    LVAD=Left Ventricular Assist Device

30. H02: All-cause Mortality, Heart Transplant or LVAD [5 years post randomization]

31. H01: All-cause Mortality, Heart Transplant or LVAD [10 years post randomization]

    LVAD=Left Ventricular Assist Device

32. H01: All-cause (Unplanned and Elective) Hospitalization [5 years post randomization]

33. H02: All-cause (Unplanned and Elective) Hospitalization [5 years post randomization]

34. H01: All-cause (Unplanned and Elective) Hospitalization [10 years post randomization]

35. H01: 6 Minute Walk Distance [From randomization to 24 month follow-up]

36. H02: 6 Minute Walk Distance [From randomization to 24 month follow-up]

37. H01: Exercise Duration [From randomization to 24 months follow-up]

    Record the total duration of exercise in minutes and seconds for patients performing the modified Bruce exercise treadmill test

38. H02: Exercise Duration [From randomization to 24 months follow-up]

    Record the total duration of exercise in minutes and seconds for patients performing the modified Bruce exercise treadmill test

39. H01: LVEF by ECHO Core Lab During Follow-up [From randomization to 24 months follow-up]

    Left ventricular ejection fraction (LVEF) measured by Echocardiography (ECHO) core lab

40. H02: LVEF by ECHO Core Lab During Follow-up [From randomization to 24 months follow-up]

    Left ventricular ejection fraction (LVEF) measured by Echocardiography (ECHO) core lab

41. H01: LVEF by RN Core Lab During Follow-up [From randomization to 24 months follow-up]

    Left ventricular ejection fraction (LVEF) measured by radionuclide (RN) core lab.

42. H02: LVEF by RN Core Lab During Follow-up [From randomization to 24 months follow-up]

    Left ventricular ejection fraction (LVEF) measured by radionuclide (RN) core lab.

43. H01: LVEF by CMR Core Lab During Follow-up [From randomization to 24 months follow-up]

    Left ventricular ejection fraction (LVEF) measured by cardiovascular magnetic resonance (CMR) core lab.

44. H02: LVEF by CMR Core Lab During Follow-up [From randomization to 24 months follow-up]

    Left ventricular ejection fraction (LVEF) measured by cardiovascular magnetic resonance (CMR) core lab.

45. H01: B-type Natriuretic Peptide (BNP) [From randomization to 24 months follow-up]

    B-type natriuretic peptide (BNP) by Neurohormonal/cytokine/genetic (NCG) core lab during follow-up

46. H02: B-type Natriuretic Peptide (BNP) [From randomization to 24 months follow-up]

    B-type natriuretic peptide (BNP) by Neurohormonal/cytokine/genetic (NCG) core lab during follow-up

47. H01: SF-36 Mental Health Subscale [From enrollment to 3-year follow-up]

    Short Form 36 Health Status Questionnaire (SF-36) Mental Health Subscale: These 5 items assess anxiety, depression, emotional control, and psychological well-being. Response choices range from "All of the time" (1) to "None of the time" (6). Item values are summed and then transformed to a 0-100 scale where higher scores indicate better mental health. (Final scores are normalized to a mean of 50 and standard deviation of 10.)

48. H02: SF-36 Mental Health Subscale [From enrollment to 3-year follow-up]

    These 5 items assess anxiety, depression, emotional control, and psychological well-being. Response choices range from "All of the time" (1) to "None of the time" (6). Item values are summed and then transformed to a 0-100 scale where higher scores indicate better mental health. (Final scores are normalized to a mean of 50 and standard deviation of 10.)

49. H01:SF-36 Role Physical Subscale [From enrollment to 3-year follow-up]

    These 4 items assess limitations and difficulty performing work or other usual activities as a result of one's physical health. Response choices are either "Yes" (1) or "No" (2). Item values are summed and then transformed to a 0-100 scale where higher scores indicate better outcomes. (Final scores are normalized to a mean of 50 and standard deviation of 10.)

50. H02: SF-36 Role Physical Subscale [From enrollment to 3-year follow-up]

    These 4 items assess limitations and difficulty performing work or other usual activities as a result of one's physical health. Response choices are either "Yes" (1) or "No" (2). Item values are summed and then transformed to a 0-100 scale where higher scores indicate better outcomes. (Final scores are normalized to a mean of 50 and standard deviation of 10.)

51. H01:SF-36 Role Emotional Subscale [From enrollment to 3-year follow-up]

    These 3 items assess limitations and difficulty performing work or other usual activities as a result of any emotional problems (such as feeling depressed or anxious). Response choices are either "Yes" (1) or "No" (2). Item values are summed and then transformed to a 0-100 scale where higher scores indicate better outcomes. (Final scores are normalized to a mean of 50 and standard deviation of 10.)

52. H02: SF-36 Role Emotional Subscale [From enrollment to 3-year follow-up]

    These 3 items assess limitations and difficulty performing work or other usual activities as a result of any emotional problems (such as feeling depressed or anxious). Response choices are either "Yes" (1) or "No" (2). Item values are summed and then transformed to a 0-100 scale where higher scores indicate better outcomes. (Final scores are normalized to a mean of 50 and standard deviation of 10.)

53. H01:SF-36 Social Functioning Subscale [From enrollment to 3-year follow-up]

    These 2 items assess the limitations on social activities with others. Response choices range from "Extremely" or "All of the time" (1) to "Not at all" or "None of the time" (5). Item values are summed and then transformed to a 0-100 scale where higher scores indicate better social functioning. (Final scores are normalized to a mean of 50 and standard deviation of 10.)

54. H02: SF-36 Social Functioning Subscale [From enrollment to 3-year follow-up]

    These 2 items assess the limitations on social activities with others. Response choices range from "Extremely" or "All of the time" (1) to "Not at all" or "None of the time" (5). Item values are summed and then transformed to a 0-100 scale where higher scores indicate better social functioning. (Final scores are normalized to a mean of 50 and standard deviation of 10.)

55. H01:SF-36 Vitality Subscale [From enrollment to 3-year follow-up]

    These 4 items assess energy level and fatigue. Response choices range from "All of the time" (1) to "None of the time" (6). Item values are summed and then transformed to a 0-100 scale where higher scores indicate better vitality. (Final scores are normalized to a mean of 50 and standard deviation of 10.)

56. H02: SF-36 Vitality Subscale [From enrollment to 3-year follow-up]

    These 4 items assess energy level and fatigue. Response choices range from "All of the time" (1) to "None of the time" (6). Item values are summed and then transformed to a 0-100 scale where higher scores indicate better vitality. (Final scores are normalized to a mean of 50 and standard deviation of 10.)

57. H01:SF-12 Physical Component Summary (PCS) Scale [From enrollment to 3-year follow-up]

    Twelve items that reflect both physical and mental health are selected from the SF-36 subscales and combined according to an algebraic formula using published weights and constants: (a) First, the items are coded so that a higher value indicates better health; (b) then indicator variables (1/0) are created for the item response choice categories; (c) next, the 35 indicator variables are weighted using "physical" regression weights from the general US population and summed to produce the PCS-12 score; and (d) finally, a normalized score (with a mean of 50 and standard deviation of 10) is obtained by adding the "physical" constant from the scoring table to the sum of the 35 products.

58. H02: SF-12 Physical Component Summary (PCS) Scale [From enrollment to 3-year follow-up]

    Twelve items that reflect both physical and mental health are selected from the SF-36 subscales and combined according to an algebraic formula using published weights and constants: (a) First, the items are coded so that a higher value indicates better health; (b) then indicator variables (1/0) are created for the item response choice categories; (c) next, the 35 indicator variables are weighted using "physical" regression weights from the general US population and summed to produce the PCS-12 score; and (d) finally, a normalized score (with a mean of 50 and standard deviation of 10) is obtained by adding the "physical" constant from the scoring table to the sum of the 35 products.

59. H01: SF-12 Mental Component Summary (MCS) Scale [From enrollment to 3-year follow-up]

    Twelve items that reflect both physical and mental health are selected from the SF-36 subscales and combined according to an algebraic formula using published weights and constants: (a) First, the items are coded so that a higher value indicates better health; (b) then indicator variables (1/0) are created for the item response choice categories; (c) next, the 35 indicator variables are weighted using "mental" regression weights from the general US population and summed to produce the MCS-12 score; and (d) finally, a normalized score (with a mean of 50 and standard deviation of 10) is obtained by adding the "mental" constant from the scoring table to the sum of the 35 products.

60. H02: SF-12 Mental Component Summary (MCS) Scale [From enrollment to 3-year follow-up]

    Twelve items that reflect both physical and mental health are selected from the SF-36 subscales and combined according to an algebraic formula using published weights and constants: (a) First, the items are coded so that a higher value indicates better health; (b) then indicator variables (1/0) are created for the item response choice categories; (c) next, the 35 indicator variables are weighted using "mental" regression weights from the general US population and summed to produce the MCS-12 score; and (d) finally, a normalized score (with a mean of 50 and standard deviation of 10) is obtained by adding the "mental" constant from the scoring table to the sum of the 35 products.

61. H01: KCCQ Physical Limitation Scale [From enrollment to 3-year follow-up]

    Kansas City Cardiomyopathy Questionnaire (KCCQ)Physical Limitation Scale: These 6 items assess ability to perform various activities of daily living. Response choices range from "Extremely limited" (1) to "Not at all limited" (5). Mean scores are transformed to a 0-100 scale with high scores representing better outcomes. .

62. H02: KCCQ Physical Limitation Scale [From enrollment to 3-year follow-up]

    These 6 items assess ability to perform various activities of daily living. Response choices range from "Extremely limited" (1) to "Not at all limited" (5). Mean scores are transformed to a 0-100 scale with high scores representing better outcomes.

63. H01: KCCQ Symptom Stability [From enrollment to 3-year follow-up]

    This item assesses changes in shortness of breath or fatigue over the past 2 weeks. Response choices range from "Much worse" (1) to "Much better" (5). Item score is transformed to a 0-100 scale with a high score representing a better outcome. .

64. H02: KCCQ Symptom Stability [From enrollment to 3-year follow-up]

    This item assesses changes in shortness of breath or fatigue over the past 2 weeks. Response choices range from "Much worse" (1) to "Much better" (5). Item score is transformed to a 0-100 scale with a high score representing a better outcome.

65. H01: KCCQ Symptom Frequency [From enrollment to 3-year follow-up]

    These 4 items assess how many times the patient has been bothered by shortness of breath, fatigue, and ankle swelling over the past 2 weeks. Response choices vary, but they range from "Every morning" or "Every night" or "All of the time" (1) to "Never over the past 2 weeks" (either 5 or 7). Mean scores are transformed to a 0-100 scale with high scores representing better outcomes. .

66. H02: KCCQ Symptom Frequency [From enrollment to 3-year follow-up]

    These 4 items assess how many times the patient has been bothered by shortness of breath, fatigue, and ankle swelling over the past 2 weeks. Response choices vary, but they range from "Every morning" or "Every night" or "All of the time" (1) to "Never over the past 2 weeks" (either 5 or 7). Mean scores are transformed to a 0-100 scale with high scores representing better outcomes.

67. H01: KCCQ Symptom Burden [From enrollment to 3-year follow-up]

    These 3 items assess how much the patient has been bothered by shortness of breath, fatigue, and ankle swelling over the past 2 weeks. Response choices range from "extremely bothersome" (1) to "Not at all bothersome" (5). Mean scores are transformed to a 0-100 scale with high scores representing better outcomes.

68. H02: KCCQ Symptom Burden [From enrollment to 3-year follow-up]

    These 3 items assess how much the patient has been bothered by shortness of breath, fatigue, and ankle swelling over the past 2 weeks. Response choices range from "extremely bothersome" (1) to "Not at all bothersome" (5). Mean scores are transformed to a 0-100 scale with high scores representing better outcomes.

69. H01: KCCQ Total Symptoms [From enrollment to 3-year follow-up]

    This score represents the mean of the Symptom Frequency and Symptom Burden scores. Mean scores are transformed to a 0-100 scale with high scores representing better outcomes. .

70. H02: KCCQ Total Symptoms [From enrollment to 3-year follow-up]

    This score represents the mean of the Symptom Frequency and Symptom Burden scores. Mean scores are transformed to a 0-100 scale with high scores representing better outcomes.

71. H01: KCCQ Quality-of-Life Scale [From enrollment to 3-year follow-up]

    These 3 items assess the effect of heart failure on the patient's enjoyment of life. Response choices range from 1 (worst state) to 5 (best state). Mean scores are transformed to a 0-100 scale with high scores representing better outcomes. .

72. H02: KCCQ Quality-of-Life Scale [From enrollment to 3-year follow-up]

    These 3 items assess the effect of heart failure on the patient's enjoyment of life. Response choices range from 1 (worst state) to 5 (best state). Mean scores are transformed to a 0-100 scale with high scores representing better outcomes.

73. H01: KCCQ Social Limitation [From enrollment to 3-year follow-up]

    These 4 items assess how much heart failure has affected the patient's lifestyle. Response choices range from "Severely limited" (1) to "Did not limit at all" (5). Mean scores are transformed to a 0-100 scale with high scores representing better outcomes. .

74. H02: KCCQ Social Limitation [From enrollment to 3-year follow-up]

    These 4 items assess how much heart failure has affected the patient's lifestyle. Response choices range from "Severely limited" (1) to "Did not limit at all" (5). Mean scores are transformed to a 0-100 scale with high scores representing better outcomes.

75. H01: KCCQ Clinical Summary Score [From enrollment to 3-year follow-up]

    This score represents the mean of the Physical Limitation and Total Symptom scores. Mean scores are transformed to a 0-100 scale with high scores representing better outcomes. .

76. H02: KCCQ Clinical Summary Score [From enrollment to 3-year follow-up]

    This score represents the mean of the Physical Limitation and Total Symptom scores. Mean scores are transformed to a 0-100 scale with high scores representing better outcomes.

77. H01: KCCQ Overall Summary Score [From enrollment to 3-year follow-up]

    This score represents the mean of these 4 scores: Physical Limitation, Total Symptom, Quality of Life, and Social Limitation. Mean scores are transformed to a 0-100 scale with high scores representing better outcomes. .

78. H02: KCCQ Overall Summary Score [From enrollment to 3-year follow-up]

    This score represents the mean of these 4 scores: Physical Limitation, Total Symptom, Quality of Life, and Social Limitation. Mean scores are transformed to a 0-100 scale with high scores representing better outcomes.

79. H01: Seattle Angina Questionnaire (SAQ) Anginal Frequency Subscale [From enrollment to 3-year follow-up]

    These 2 items assess the frequency of chest pain over the last 4 weeks. Response choices range from "4 or more times a day" (1) to "None" (6). The mean response is transformed to a 0-100 scale where higher scores reflect less frequent angina. .

80. H02: Seattle Angina Questionnaire (SAQ) Anginal Frequency Subscale [From enrollment to 3-year follow-up]

    These 2 items assess the frequency of chest pain over the last 4 weeks. Response choices range from "4 or more times a day" (1) to "None" (6). The mean response is transformed to a 0-100 scale where higher scores reflect less frequent angina.

81. H01: Seattle Angina Questionnaire (SAQ) Anginal Stability Subscale [From enrollment to 3-year follow-up]

    This item assesses the change in chest pain over the last 4 weeks. Response choices range from "Much more often" (1) to "None" (6). The mean response is transformed to a 0-100 scale where 50 represents no change and a higher score indicates less angina. .

82. H02: Seattle Angina Questionnaire (SAQ) Anginal Stability Subscale [From enrollment to 3-year follow-up]

    This item assesses the change in chest pain over the last 4 weeks. Response choices range from "Much more often" (1) to "None" (6). The mean response is transformed to a 0-100 scale where 50 represents no change and a higher score indicates less angina.

83. H01:Seattle Angina Questionnaire (SAQ) Quality-of-Life Subscale [From enrollment to 3-year follow-up]

    These 3 items measure the patient's general satisfaction with life. Response choices range from 1 (least enjoyment) to 5 (high satisfaction). The mean score is transformed to a 0-100 scale where higher scores reflect better outcomes. .

84. H02: Seattle Angina Questionnaire (SAQ) Quality-of-Life Subscale [From enrollment to 3-year follow-up]

    These 3 items measure the patient's general satisfaction with life. Response choices range from 1 (least enjoyment) to 5 (high satisfaction). The mean score is transformed to a 0-100 scale where higher scores reflect better outcomes.

85. H01: EQ-5D Visual Analog Scale [From enrollment to 3-year follow-up]

    Euro QoL 5 Dimensions Quality of Life Instrument (EQ-5D): This 0-100 scale records the patient's self-rated health on a vertical scale where 0 = worst imaginable health and 100 = perfect health. .

86. H02: EQ-5D Visual Analog Scale [From enrollment to 3-year follow-up]

    This 0-100 scale records the patient's self-rated health on a vertical scale where 0 = worst imaginable health and 100 = perfect health.

87. H01: EQ-5D Health Status Index Score [From enrollment to 3-year follow-up]

    This 5-item scale describes a patient's health in terms of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Choices for each dimension are "No problems" (1), "Moderate problems" (2), or "Extreme problems" (3). A scoring algorithm with utility weights is then applied to these 5 items to generate index scores ranging from -0.11 (i.e., 33333) to 1.0 (i.e., 11111) on a scale where 0.0 = death and 1.0 = perfect health. These scores were multiplied by 100 to produce a scale from -11 to 100 that more closely resembles the Visual Analog Scale. .

88. H02: EQ-5D Health Status Index Score [From enrollment to 3-year follow-up]

    This 5-item scale describes a patient's health in terms of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Choices for each dimension are "No problems" (1), "Moderate problems" (2), or "Extreme problems" (3). A scoring algorithm with utility weights is then applied to these 5 items to generate index scores ranging from -0.11 (i.e., 33333) to 1.0 (i.e., 11111) on a scale where 0.0 = death and 1.0 = perfect health. (These scores can be multiplied by 100 to produce a scale from -11 to 100 that more closely resembles the Visual Analog Scale.)

89. H01: Percentage of Patients With a Score of >= 16 on the Center for Epidemiological Studies Depression (CES-D) Scale [From enrollment to 3-year follow-up]

    These 20 items assess depressive symptomatology, and responses choices range from "Rarely or none of the time" (0) to "Most or all of the time" (3). Scale scores can therefore range from 0 to 60, although scores greater than or equal to 16 are considered high. .

90. H02: Percentage of Patients With a Score of >= 16 on the Center for Epidemiological Studies Depression (CES-D) Scale [From enrollment to 3-year follow-up]

    These 20 items assess depressive symptomatology, and responses choices range from "Rarely or none of the time" (0) to "Most or all of the time" (3). Scale scores can therefore range from 0 to 60, although scores greater than or equal to 16 are considered high.

91. H01: Cardiac Self-Efficacy (CSE) Maintain Functioning Subscale [From enrollment to 3-year follow-up]

    These 5 items assess patients' ability to maintain their usual social, family, and physical activities. Response choices range from "Not at all confident" (1) to "Completely confident" (5). The mean score is transformed to a 0-100 scale where higher scores reflect more confidence. .

92. H02: Cardiac Self-Efficacy (CSE) Maintain Functioning Subscale [From enrollment to 3-year follow-up]

    These 5 items assess patients' ability to maintain their usual social, family, and physical activities. Response choices range from "Not at all confident" (1) to "Completely confident" (5). The mean score is transformed to a 0-100 scale where higher scores reflect more confidence.

93. H01: Cardiac Self-Efficacy (CSE) Control Symptoms Subscale [From enrollment to 3-year follow-up]

    These 8 items assess patients' ability to control symptoms such as chest pain and breathlessness by taking their medications and adjusting their activity levels. Response choices range from "Not at all confident" (1) to "Completely confident" (5). The mean score is transformed to a 0-100 scale where higher scores reflect more confidence. .

94. H02: Cardiac Self-Efficacy (CSE) Control Symptoms Subscale [From enrollment to 3-year follow-up]

    These 8 items assess patients' ability to control symptoms such as chest pain and breathlessness by taking their medications and adjusting their activity levels. Response choices range from "Not at all confident" (1) to "Completely confident" (5). The mean score is transformed to a 0-100 scale where higher scores reflect more confidence.

95. H01: General Health Rating Scale [From enrollment to 3-year follow-up]

    This single item asks patients to describe their health status over the past month on a scale from 0 to 100, where 0 = death and 100 = excellent health. .

96. H02: General Health Rating Scale [From enrollment to 3-year follow-up]

    This single item asks patients to describe their health status over the past month on a scale from 0 to 100, where 0 = death and 100 = excellent health.

97. H01: Cost of Care [index hospital admission]

    Hospital costs and physician fees for US patients

98. H02: Cost of Care [index hospital admission]

    Hospital costs and physician fees for US patients

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 100 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• LV less than 35%, as defined by echocardiogram, left ventriculogram, CMR, or gated single photon emission computed tomography (SPECT) studies

• Coronary anatomy suitable for revascularization

Exclusion Criteria:

• Failure to provide informed consent.

• Aortic valvular heart disease clearly indicating the need for aortic valve repair or replacement.

• Cardiogenic shock (within 72 hours of randomization), as defined by the need for intraaortic balloon support or the requirement for intravenous inotropic support.

• Plan for percutaneous intervention of CAD.

• Recent acute MI judged to be an important cause of left ventricular dysfunction.

• History of more than 1 prior coronary bypass operation.

• Noncardiac illness with a life expectancy of less than 3 years.

• Noncardiac illness imposing substantial operative mortality.

• Conditions/circumstances likely to lead to poor treatment adherence (eg, history of poor compliance, alcohol or drug dependency, psychiatric illness, no fixed abode).

• Previous heart, kidney, liver, or lung transplantation.

• Current participation in another clinical trial in which a patient is taking an investigational drug or receiving an investigational medical device.

MED Therapy Eligibility Criteria

• Absence of left main CAD as defined by an intraluminal stenosis of 50% or greater.

• Absence of CCS III angina or greater (angina markedly limiting ordinary activity).

SVR Eligibility Criterion

• Dominant akinesia or dyskinesia of the anterior left ventricular wall amenable to SVR.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Duke University Medical Center	Durham	North Carolina	United States	27715

Sponsors and Collaborators

• Duke University
• National Heart, Lung, and Blood Institute (NHLBI)

Investigators

• Principal Investigator: Robert Bonow, Radionuclide Core Lab, Northwestern University
• Principal Investigator: Arthur Feldman, Neurohormonal Core Lab, Jefferson University
• Principal Investigator: Eric Velazquez, MD, Clinical Coordinating Center, Duke University
• Principal Investigator: Kerry Lee, Data Coordinating Center, Duke University
• Principal Investigator: Daniel Mark, Economics and Quality of Life Core Lab, Duke University
• Principal Investigator: Jae Oh, Echocardiographic Core Lab, Mayo Clinic
• Principal Investigator: Gerald Pohost, Magnetic Resonance Imaging Core Lab, University of Southern California
• Study Chair: Jean Rouleau, Université de Montréal
• Principal Investigator: Julio A Panza, MD, Medstar Health Research Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

• Velazquez EJ, Lee KL, O'Connor CM, Oh JK, Bonow RO, Pohost GM, Feldman AM, Mark DB, Panza JA, Sopko G, Rouleau JL, Jones RH; STICH Investigators. The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. J Thorac Cardiovasc Surg. 2007 Dec;134(6):1540-7.

• Responsible Party: Duke University
• ClinicalTrials.gov Identifier: NCT00023595
• Other Study ID Numbers: Pro00018940; U01HL069009; U01HL069010; U01HL069011; U01HL069012; U01HL069013; U01HL069015; U01HL072683; R01HL105853; Pro00010463
• First Posted: Sep 11, 2001
• Last Update Posted: Sep 19, 2019
• Last Verified: Sep 1, 2019

• Additional relevant MeSH terms: Heart Failure; Cardiovascular Diseases; Heart Diseases; Coronary Disease

Study Results

Participant Flow

Recruitment Details	Pts were assigned to 1 of 3 strata before randomization. All pts in stratum C and some pts in stratum B were randomly assigned to med therapy + CABG or med therapy + CABG + SVR (Hypothesis 2 component of the trial-HO2). 76 of stratum B pts who were randomized to med therapy + CABG group belong to both H01 and H02.
Pre-assignment Detail	Stratum A: eligible for med. therapy alone or med therapy + CABG; Stratum C: eligible for med therapy + CABG or med therapy + CABG + SVR; Stratum B: eligible for all 3 treatment options. All pts in stratum A and some of the pts in stratum B were randomized to either med therapy alone or med therapy + CABG (Hypothesis 1 of the STICH trial--H01).

Arm/Group Title	H01: Medication	H01: Medication + CABG	H01+H02: Medication + CABG	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	50% of H01 patients were randomized to this medical therapy alone arm. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	50% of H01 patients were randomized to medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	This group includes those 76 patients who belong to both H01 and H02. These patients were randomized to medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm.	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm.
Period Title: 5 Year Follow up
STARTED	602	534	76	423	501
COMPLETED	600	532	75	416	498
NOT COMPLETED	2	2	1	7	3
Period Title: 5 Year Follow up
STARTED	602	534	76	0	0
COMPLETED	590	524	73	0	0
NOT COMPLETED	12	10	3	0	0

Baseline Characteristics

Arm/Group Title	H01: Medication	H01: Medication + CABG	H01+H02: Medication + CABG	H02: Medication+CABG	H02: Medication+CABG+SVR	Total
Arm/Group Description	50% of H01 patients were randomized to this medical therapy alone arm. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	50% of H01 patients were randomized to medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	This group includes those 76 patients who belong to both H01 and H02. These patients were randomized to medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm.	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm.	Total of all reporting groups
Overall Participants	602	534	76	423	501	2136
Age (years) [Median (Inter-Quartile Range) ]
Median (Inter-Quartile Range) [years]	59	60	61	62	62	60
Sex: Female, Male (Count of Participants)
Female	75 12.5%	64 12%	9 11.8%	69 16.3%	69 13.8%	286 13.4%
Male	527 87.5%	470 88%	67 88.2%	354 83.7%	432 86.2%	1850 86.6%

Outcome Measures

1. Primary Outcome

Title	H01: All Cause Mortality
Time Frame	5 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	602	610
Number [participants]	244 40.5%	218 40.8%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.12
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.86
	Confidence Interval	(2-Sided) 95%; 0.72 to 1.04
	Parameter Dispersion	Type: Value:
	Estimation Comments	Hazard Ratio is for (H01: Medication +CABG) versus (H01: Medication)

2. Primary Outcome

Title	H01: All Cause Mortality
Time Frame	10 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	602	610
Number [participants]	398 66.1%	359 67.2%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.02
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.84
	Confidence Interval	(2-Sided) 95%; 0.73 to 0.97
	Parameter Dispersion	Type: Value:
	Estimation Comments	Hazard Ratio is for (H01: Medication +CABG) versus (H01: Medication)

3. Primary Outcome

Title	H02: All-cause Mortality or Cardiovascular Hospitalization
Time Frame	5 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	H02: Medication+CABG+SVR	Total H02: Medication+CABG
Arm/Group Description	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm.	H02 patients were randomized to medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	501	499
Number [participants]	289 48%	292 54.7%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.90
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.99
	Confidence Interval	(2-Sided) 95%; 0.84 to 1.17
	Parameter Dispersion	Type: Value:
	Estimation Comments	Hazard Ratio is for (H02: Medication + CABG + SVR) versus (H02: Medication + CABG)

4. Secondary Outcome

Title	H01: Cardiovascular Mortality (Defined as Sudden Death or Death Attributed to Recurrent MI, HF, a Cardiovascular Procedure, Stroke, or Other Cardiovascular Etiology).
Time Frame	10 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	610	602
Number [participants]	247 41%	297 55.6%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.006
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio, log
	Estimated Value	0.79
	Confidence Interval	(2-Sided) 95%; 0.66 to 0.93
	Parameter Dispersion	Type: Value:
	Estimation Comments	Hazard Ratio is for (H01: Medication +CABG) versus (H01: Medication)

5. Secondary Outcome

Title	H01: Cardiovascular Mortality (Defined as Sudden Death or Death Attributed to Recurrent MI, HF, a Cardiovascular Procedure, Stroke, or Other Cardiovascular Etiology).
Time Frame	5 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	610	602
Number [participants]	168 27.9%	201 37.6%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.05
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.81
	Confidence Interval	(2-Sided) 95%; 0.66 to 1.00
	Parameter Dispersion	Type: Value:
	Estimation Comments	Hazard Ratio is for (H01: Medication +CABG) versus (H01: Medication)

6. Secondary Outcome

Title	H01: Mortality or Cardiovascular Hospitalization
Time Frame	up to 5 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	602	610
Number [participants]	411 68.3%	351 65.7%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.74
	Confidence Interval	(2-Sided) 95%; 0.64 to 0.85
	Parameter Dispersion	Type: Value:
	Estimation Comments	Hazard Ratio is for (H01: Medication +CABG) versus (H01: Medication)

7. Secondary Outcome

Title	H01: Mortality or Cardiovascular Hospitalization
Time Frame	up to 10 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	602	610
Number [participants]	524 87%	467 87.5%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.72
	Confidence Interval	(2-Sided) 95%; 0.64 to 0.82
	Parameter Dispersion	Type: Value:
	Estimation Comments	Hazard Ratio is for (H01: Medication +CABG) versus (H01: Medication)

8. Secondary Outcome

Title	H02: All-cause Mortality
Time Frame	up to 5 years

Outcome Measure Data

Analysis Population Description

The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	Total H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	H02 patients were randomized to medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm.
Measure Participants	499	501
Number [participants]	141 23.4%	138 25.8%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.98
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	1.00
	Confidence Interval	(2-Sided) 95%; 0.79 to 1.26
	Parameter Dispersion	Type: Value:
	Estimation Comments	Hazard Ratio is for (H02: Medication + CABG + SVR) versus (H02: Medication + CABG)

9. Secondary Outcome

Title	H01: All-cause Mortality Within 30 Days After Randomization
Time Frame	30 days post randomization

Outcome Measure Data

Analysis Population Description

The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	602	610
Number [participants]	7 1.2%	22 4.1%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.008
	Comments
	Method	Regression, Logistic
	Comments
Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	3.19
	Confidence Interval	(2-Sided) 95%; 1.35 to 7.52
	Parameter Dispersion	Type: Value:
	Estimation Comments	Odds Ratio is for (H01: Medication +CABG) versus (H01: Medication)

10. Secondary Outcome

Title	H02: All-cause Mortality Within 30 Days After Randomization
Time Frame	30 days post randomization

Outcome Measure Data

Analysis Population Description

The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm

Arm/Group Title	Total H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	H02 patients were randomized to medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm.
Measure Participants	499	501
Number [participants]	22 3.7%	30 5.6%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.275
	Comments
	Method	Regression, Logistic
	Comments
Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	1.37
	Confidence Interval	(2-Sided) 95%; 0.78 to 2.41
	Parameter Dispersion	Type: Value:
	Estimation Comments	Odds Ratio is for (H02: Medication + CABG + SVR) versus (H02: Medication + CABG)

11. Secondary Outcome

Title	H01: All-cause Mortality or Heart-failure Hospitalization
Time Frame	5 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	602	610
Number [participants]	324 53.8%	290 54.3%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.030
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.84
	Confidence Interval	(2-Sided) 95%; 0.71 to 0.98
	Parameter Dispersion	Type: Value:
	Estimation Comments	Hazard Ratio is for (H01: Medication +CABG) versus (H01: Medication)

12. Secondary Outcome

Title	H02: All-cause Mortality or Heart-failure Hospitalization
Time Frame	5 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	Total H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	H02 patients were randomized to medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm.
Measure Participants	499	501
Number [participants]	211 35%	214 40.1%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.401
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	1.08
	Confidence Interval	(2-Sided) 95%; 0.89 to 1.31
	Parameter Dispersion	Type: Value:
	Estimation Comments	Hazard Ratio is for (H02: Medication + CABG + SVR) versus (H02: Medication + CABG)

13. Secondary Outcome

Title	H01: All-cause Mortality or Heart-failure Hospitalization
Time Frame	10 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	602	610
Number [participants]	450 74.8%	404 75.7%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.002
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.81
	Confidence Interval	(2-Sided) 95%; 0.71 to 0.93
	Parameter Dispersion	Type: Value:
	Estimation Comments	Hazard Ratio is for (H01: Medication +CABG) versus (H01: Medication)

14. Secondary Outcome

Title	H01: Heart Failure Hospitalization
Time Frame	5 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	602	610
Number [participants]	169 28.1%	127 23.8%

15. Secondary Outcome

Title	H02: Heart Failure Hospitalization
Time Frame	5 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	Total H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	H02 patients were randomized to medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm.
Measure Participants	499	501
Number [participants]	95 15.8%	99 18.5%

16. Secondary Outcome

Title	H01: Heart Failure Hospitalization
Time Frame	10 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	602	610
Number [participants]	201 33.4%	157 29.4%

17. Secondary Outcome

Title	H01: Cardiac Procedure: Heart Transplant
Time Frame	5 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	602	610
Number [participants]	3 0.5%	0 0%

18. Secondary Outcome

Title	H02: Cardiac Procedure: Heart Transplant
Time Frame	5 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	Total H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	H02 patients were randomized to medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm.
Measure Participants	499	501
Number [participants]	2 0.3%	7 1.3%

19. Secondary Outcome

Title	H01: Cardiac Procedure: Heart Transplant
Time Frame	10 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	602	610
Number [participants]	4 0.7%	1 0.2%

20. Secondary Outcome

Title	H01: Cardiac Procedure: Left Ventricular Assist Device (LVAD)
Time Frame	5 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	602	610
Number [participants]	2 0.3%	2 0.4%

21. Secondary Outcome

Title	H02: Cardiac Procedure: Left Ventricular Assist Device (LVAD)
Time Frame	5 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	Total H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	H02 patients were randomized to medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm.
Measure Participants	499	501
Number [participants]	2 0.3%	2 0.4%

22. Secondary Outcome

Title	H01: Cardiac Procedure: Left Ventricular Assist Device (LVAD)
Time Frame	10 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	602	610
Number [participants]	2 0.3%	4 0.7%

23. Secondary Outcome

Title	H01: Cardiac Procedure: Implantable Cardioverter Defibrillator (ICD)
Time Frame	5 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	602	610
Number [participants]	98 16.3%	76 14.2%

24. Secondary Outcome

Title	H02: Cardiac Procedure: Implantable Cardioverter Defibrillator (ICD)
Time Frame	5 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	Total H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	H02 patients were randomized to medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm.
Measure Participants	499	501
Number [participants]	100 16.6%	86 16.1%

25. Secondary Outcome

Title	H01: Cardiac Procedure: Implantable Cardioverter Defibrillator (ICD)
Time Frame	10 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	602	610
Number [participants]	118 19.6%	105 19.7%

26. Secondary Outcome

Title	H01: Stroke
Time Frame	5 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	602	610
Number [participants]	34 5.6%	41 7.7%

27. Secondary Outcome

Title	H01: Stroke
Time Frame	10 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	602	610
Number [participants]	41 6.8%	47 8.8%

28. Secondary Outcome

Title	H02: Stroke
Time Frame	5 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	Total H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	H02 patients were randomized to medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm.
Measure Participants	499	501
Number [participants]	31 5.1%	23 4.3%

29. Secondary Outcome

Title	H01: All-cause Mortality or Revascularization (CABG or PCI)
Description	CABG = coronary artery bypass grafting. For patients randomized to CABG or CABG +SVR group, this represents the repeat CABG received during follow-up. PCI = Percutaneous Coronary Intervention.
Time Frame	5 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	602	610
Number [participants]	333 55.3%	237 44.4%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.60
	Confidence Interval	(2-Sided) 95%; 0.51 to 0.71
	Parameter Dispersion	Type: Value:
	Estimation Comments	Hazard Ratio is for (H01: Medication +CABG) versus (H01: Medication)

30. Secondary Outcome

Title	H02: All-cause Mortality or Revascularization (CABG or PCI)
Description	CABG = coronary artery bypass grafting. For patients randomized to CABG or CABG +SVR group, this represents the repeat CABG received during follow-up. PCI = Percutaneous Coronary Intervention.
Time Frame	5 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	Total H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	H02 patients were randomized to medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm.
Measure Participants	499	501
Number [participants]	174 28.9%	152 28.5%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.414
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.91
	Confidence Interval	(2-Sided) 95%; 0.73 to 1.13
	Parameter Dispersion	Type: Value:
	Estimation Comments	Hazard Ratio is for (H02: Medication + CABG + SVR) versus (H02: Medication + CABG)

31. Secondary Outcome

Title	H01: All-cause Mortality or Revascularization (CABG or PCI)
Description	CABG = coronary artery bypass grafting. For patients randomized to CABG or CABG +SVR group, this represents the repeat CABG received during follow-up. PCI = Percutaneous Coronary Intervention.
Time Frame	10 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	602	610
Number [participants]	478 79.4%	388 72.7%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.63
	Confidence Interval	(2-Sided) 95%; 0.55 to 0.73
	Parameter Dispersion	Type: Value:
	Estimation Comments	Hazard Ratio is for (H01: Medication +CABG) versus (H01: Medication)

32. Secondary Outcome

Title	H01: All-cause Mortality, Heart Transplant or LVAD
Description	LVAD=Left Ventricular Assist Device
Time Frame	5 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	602	610
Number [participants]	245 40.7%	218 40.8%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.108
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.86
	Confidence Interval	(2-Sided) 95%; 0.72 to 1.03
	Parameter Dispersion	Type: Value:
	Estimation Comments	Hazard Ratio is for (H01: Medication +CABG) versus (H01: Medication)

33. Secondary Outcome

Title	H02: All-cause Mortality, Heart Transplant or LVAD
Time Frame	5 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	Total H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	H02 patients were randomized to medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm.
Measure Participants	499	501
Number [participants]	148 24.6%	145 27.2%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.717
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	1.05
	Confidence Interval	(2-Sided) 95%; 0.83 to 1.32
	Parameter Dispersion	Type: Value:
	Estimation Comments	Hazard Ratio is for (H02: Medication + CABG + SVR) versus (H02: Medication + CABG)

34. Secondary Outcome

Title	H01: All-cause Mortality, Heart Transplant or LVAD
Description	LVAD=Left Ventricular Assist Device
Time Frame	10 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	602	610
Number [participants]	400 66.4%	361 67.6%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.018
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.84
	Confidence Interval	(2-Sided) 95%; 0.73 to 0.97
	Parameter Dispersion	Type: Value:
	Estimation Comments	Hazard Ratio is for (H01: Medication +CABG) versus (H01: Medication)

35. Secondary Outcome

Title	H01: All-cause (Unplanned and Elective) Hospitalization
Time Frame	5 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	602	610
Number [participants]	340 56.5%	290 54.3%

36. Secondary Outcome

Title	H02: All-cause (Unplanned and Elective) Hospitalization
Time Frame	5 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	Total H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	H02 patients were randomized to medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm.
Measure Participants	499	501
Number [participants]	272 45.2%	268 50.2%

37. Secondary Outcome

Title	H01: All-cause (Unplanned and Elective) Hospitalization
Time Frame	10 years post randomization

Outcome Measure Data

Analysis Population Description

The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	602	610
Number [participants]	383 63.6%	349 65.4%

38. Secondary Outcome

Title	H01: 6 Minute Walk Distance
Time Frame	From randomization to 24 month follow-up

Outcome Measure Data

Analysis Population Description

Only patients with 6-minute walk distance data at baseline, 4 months or 24 months were analyzed.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	559	552
Baseline	333.97 (117.76)	333.04 (117.06)
4 month	364.25 (111.24)	376.46 (118.87)
Changed from baseline to 4 months	28.2 (102.44)	37.76 (108.93)
24 month	381.55 (120.86)	377.84 (122.62)
Change from baseline to 24 Months	34.11 (112.9)	31.18 (128.99)

39. Secondary Outcome

Title	H02: 6 Minute Walk Distance
Time Frame	From randomization to 24 month follow-up

Outcome Measure Data

Analysis Population Description

Only patients with 6-minute walk distance data at baseline, 4 months or 24 months were analyzed.

Arm/Group Title	Total H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	H02 patients were randomized to medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm.
Measure Participants	420	429
Baseline	339.38 (126.11)	357.23 (116.91)
4 month	385.89 (123.49)	407.03 (121.38)
Changed from baseline to 4 months	44.42 (122.64)	46.09 (113.67)
24 month	400.66 (121.67)	425.18 (121.46)
Change from baseline to 24 Months	51.51 (125.65)	55.6 (112.66)

40. Secondary Outcome

Title	H01: Exercise Duration
Description	Record the total duration of exercise in minutes and seconds for patients performing the modified Bruce exercise treadmill test
Time Frame	From randomization to 24 months follow-up

Outcome Measure Data

Analysis Population Description

Only patients with exercise duration data at baseline or 24 months were analyzed.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	269	242
Baseline	6.85 (3.4)	6.3 (3.39)
24 month	7.78 (3.32)	7.97 (3.32)
Change from baseline to 24 Months	0.71 (3.51)	0.83 (3.26)

41. Secondary Outcome

Title	H02: Exercise Duration
Description	Record the total duration of exercise in minutes and seconds for patients performing the modified Bruce exercise treadmill test
Time Frame	From randomization to 24 months follow-up

Outcome Measure Data

Analysis Population Description

Only patients with exercise duration data at baseline or 24 months were analyzed.

Arm/Group Title	Total H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description
Measure Participants	119	138
Baseline	6.19 (3.42)	7.16 (3.47)
24 month	7.67 (3.3)	8.41 (3.41)
Change from baseline to 24 Months	1.15 (3.01)	0.47 (3.42)

42. Secondary Outcome

Title	H01: LVEF by ECHO Core Lab During Follow-up
Description	Left ventricular ejection fraction (LVEF) measured by Echocardiography (ECHO) core lab
Time Frame	From randomization to 24 months follow-up

Outcome Measure Data

Analysis Population Description

Only patients with ECHO LVEF data at baseline, 4 months or 24 months were analyzed.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	584	589
Baseline	28.69 (8.33)	28.43 (8.24)
4 month	30.83 (9.41)	30.66 (10.73)
Changed from baseline to 4 months	2.21 (8.8)	2.06 (10.06)
24 month	31.39 (10.75)	31.15 (11.14)
Change from baseline to 24 Months	2.2 (11.31)	2.22 (10.67)

43. Secondary Outcome

Title	H02: LVEF by ECHO Core Lab During Follow-up
Description	Left ventricular ejection fraction (LVEF) measured by Echocardiography (ECHO) core lab
Time Frame	From randomization to 24 months follow-up

Outcome Measure Data

Analysis Population Description

Only patients with ECHO LVEF data at baseline, 4 months or 24 months were analyzed.

Arm/Group Title	Total H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description
Measure Participants	484	484
Baseline	29.13 (7.74)	29.49 (8.23)
4 month	31.47 (10.4)	33.35 (9.79)
Changed from baseline to 4 months	2.16 (10.23)	3.04 (9.7)
24 month	31.89 (11.38)	33.55 (10.91)
Change from baseline to 24 Months	2.24 (11.11)	2.93 (10.95)

44. Secondary Outcome

Title	H01: LVEF by RN Core Lab During Follow-up
Description	Left ventricular ejection fraction (LVEF) measured by radionuclide (RN) core lab.
Time Frame	From randomization to 24 months follow-up

Outcome Measure Data

Analysis Population Description

Only patients with RN LVEF data at Baseline, 4-months or 24-months were analyzed.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	250	255
Baseline	26.83 (8.66)	26.66 (8.41)
4 month	27.2 (9.5)	27.81 (9.73)
Changed from baseline to 4 months	0.99 (5.88)	2.65 (6.36)
24 month	30.65 (10.74)	27.79 (9.05)
Change from baseline to 24 Months	3.99 (8.24)	1.77 (5.63)

45. Secondary Outcome

Title	H02: LVEF by RN Core Lab During Follow-up
Description	Left ventricular ejection fraction (LVEF) measured by radionuclide (RN) core lab.
Time Frame	From randomization to 24 months follow-up

Outcome Measure Data

Analysis Population Description

Only patients with RN LVEF data at Baseline, 4-months or 24-months were analyzed.

Arm/Group Title	Total H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description
Measure Participants	214	216
Baseline	27.14 (8.18)	26.55 (7.83)
4 month	30.65 (10.41)	33.5 (9.42)
Changed from baseline to 4 months	2.23 (7.11)	6.49 (7.91)
24 month	29.95 (10.97)	34.2 (10.3)
Change from baseline to 24 Months	2.01 (9.58)	6.79 (9.12)

46. Secondary Outcome

Title	H01: LVEF by CMR Core Lab During Follow-up
Description	Left ventricular ejection fraction (LVEF) measured by cardiovascular magnetic resonance (CMR) core lab.
Time Frame	From randomization to 24 months follow-up

Outcome Measure Data

Analysis Population Description

Only patients with CMR LVEF data at baseline, 4 months or 24 months were analyzed.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	50	68
Baseline	29.51 (11.02)	23.35 (9.49)
4 month	28.6 (11.11)	28.63 (13.16)
Changed from baseline to 4 months	0.07 (8.82)	2.85 (12.87)
24 month	32.72 (14.7)	31.47 (9.06)
Change from baseline to 24 Months	-1.09 (10.63)	2.13 (13.27)

47. Secondary Outcome

Title	H02: LVEF by CMR Core Lab During Follow-up
Description	Left ventricular ejection fraction (LVEF) measured by cardiovascular magnetic resonance (CMR) core lab.
Time Frame	From randomization to 24 months follow-up

Outcome Measure Data

Analysis Population Description

Only patients with CMR LVEF data at baseline, 4 months or 24 months were analyzed.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	207	196
Baseline	27.82 (10.26)	27.25 (11.47)
4 month	31.65 (13.53)	34.37 (13.41)
Changed from baseline to 4 months	2.84 (11.86)	7.1 (11.86)
24 month	28.46 (10.57)	33.1 (13.79)
Change from baseline to 24 Months	-0.51 (14.61)	5.39 (13.23)

48. Secondary Outcome

Title	H01: B-type Natriuretic Peptide (BNP)
Description	B-type natriuretic peptide (BNP) by Neurohormonal/cytokine/genetic (NCG) core lab during follow-up
Time Frame	From randomization to 24 months follow-up

Outcome Measure Data

Analysis Population Description

Only patients with BNP data at baseline or 4 months were analyzed.

Arm/Group Title	H01: Medication	Total H01: Medication + CABG
Arm/Group Description	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.
Measure Participants	314	325
Baseline	497.29 (627.49)	478.73 (521.11)
4 month	408.69 (413.27)	484.39 (554.42)
Changed from baseline to 4 months	-20.65 (405.44)	33.37 (566.62)

49. Secondary Outcome

Title	H02: B-type Natriuretic Peptide (BNP)
Description	B-type natriuretic peptide (BNP) by Neurohormonal/cytokine/genetic (NCG) core lab during follow-up
Time Frame	From randomization to 24 months follow-up

Outcome Measure Data

Analysis Population Description

Only patients with BNP data at baseline or 4 months were analyzed.

Arm/Group Title	Total H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description
Measure Participants	386	392
Baseline	453.73 (563.1)	452.45 (665.06)
4 month	460.14 (508.35)	467.83 (579.42)
Changed from baseline to 4 months	19.75 (600.26)	72.23 (554.2)

50. Secondary Outcome

Title	H01: SF-36 Mental Health Subscale
Description	Short Form 36 Health Status Questionnaire (SF-36) Mental Health Subscale: These 5 items assess anxiety, depression, emotional control, and psychological well-being. Response choices range from "All of the time" (1) to "None of the time" (6). Item values are summed and then transformed to a 0-100 scale where higher scores indicate better mental health. (Final scores are normalized to a mean of 50 and standard deviation of 10.)
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	597	584
Baseline	43.7 (11.8)	44.4 (11.8)
4 Months	48.2 (10.2)	47.2 (11.2)
12 Months	48.8 (11.1)	47.0 (11.8)
24 Months	48.6 (10.5)	46.8 (11.8)
36 Months	48.5 (11.1)	48.2 (10.8)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.015
	Comments	4 months
	Method	Chi-squared
	Comments	H01 P-values were based on the Chi-Square test applied to maximum likelihood estimates derived from an adjusted mixed model.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.002
	Comments	12 months
	Method	Chi-squared
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.011
	Comments	24 months
	Method	Chi-squared
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.44
	Comments	36 months
	Method	Chi-squared
	Comments

51. Secondary Outcome

Title	H02: SF-36 Mental Health Subscale
Description	These 5 items assess anxiety, depression, emotional control, and psychological well-being. Response choices range from "All of the time" (1) to "None of the time" (6). Item values are summed and then transformed to a 0-100 scale where higher scores indicate better mental health. (Final scores are normalized to a mean of 50 and standard deviation of 10.)
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm
Measure Participants	489	481
Baseline	41	41
4 Months	50	50
12 Months	53	50
24 Months	50	50
36 Months	50	50

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.91
	Comments	Baseline
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.62
	Comments	4 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.04
	Comments	12 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.96
	Comments
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.78
	Comments
	Method	Wilcoxon (Mann-Whitney)
	Comments

52. Secondary Outcome

Title	H01:SF-36 Role Physical Subscale
Description	These 4 items assess limitations and difficulty performing work or other usual activities as a result of one's physical health. Response choices are either "Yes" (1) or "No" (2). Item values are summed and then transformed to a 0-100 scale where higher scores indicate better outcomes. (Final scores are normalized to a mean of 50 and standard deviation of 10.)
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	581	569
Baseline	36.1 (10.9)	36.6 (11.2)
4 Months	43.0 (11.8)	42.6 (11.8)
12 Months	45.7 (11.4)	43.1 (12.2)
24 Months	46.6 (11.4)	44.7 (12.2)
36 Months	46.0 (11.2)	44.8 (11.6)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.31
	Comments	4 months
	Method	Chi-squared
	Comments	H01 P-values were based on the Chi-Square test applied to maximum likelihood estimates derived from an adjusted mixed model.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.002
	Comments	12 months
	Method	Chi-squared
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments	24 months
Statistical Test of Hypothesis	p-Value	0.028
	Comments
	Method	Chi-squared
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.079
	Comments	36 months
	Method	Chi-squared
	Comments

53. Secondary Outcome

Title	H02: SF-36 Role Physical Subscale
Description	These 4 items assess limitations and difficulty performing work or other usual activities as a result of one's physical health. Response choices are either "Yes" (1) or "No" (2). Item values are summed and then transformed to a 0-100 scale where higher scores indicate better outcomes. (Final scores are normalized to a mean of 50 and standard deviation of 10.)
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm
Measure Participants	466	466
Baseline	28	28
4 Months	42	42
12 Months	49	49
24 Months	49	49
36 Months	49	56

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.74
	Comments	Baseline
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.61
	Comments	4 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.78
	Comments
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.94
	Comments	24 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.29
	Comments	36 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

54. Secondary Outcome

Title	H01:SF-36 Role Emotional Subscale
Description	These 3 items assess limitations and difficulty performing work or other usual activities as a result of any emotional problems (such as feeling depressed or anxious). Response choices are either "Yes" (1) or "No" (2). Item values are summed and then transformed to a 0-100 scale where higher scores indicate better outcomes. (Final scores are normalized to a mean of 50 and standard deviation of 10.)
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	588	582
Baseline	39.0 (14.2)	40.0 (14.4)
4 Months	45.3 (13.2)	44.6 (13.4)
12 Months	46.4 (12.8)	45.9 (13.3)
24 Months	47.5 (12.1)	46.8 (12.8)
36 Months	48.0 (11.8)	47.0 (12.4)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.063
	Comments	4 months
	Method	Chi-squared
	Comments	H01 P-values were based on the Chi-Square test applied to maximum likelihood estimates derived from an adjusted mixed model.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.187
	Comments	12 months
	Method	Chi-squared
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.168
	Comments	24 months
	Method	Chi-squared
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.050
	Comments	36 months
	Method	Chi-squared
	Comments

55. Secondary Outcome

Title	H02: SF-36 Role Emotional Subscale
Description	These 3 items assess limitations and difficulty performing work or other usual activities as a result of any emotional problems (such as feeling depressed or anxious). Response choices are either "Yes" (1) or "No" (2). Item values are summed and then transformed to a 0-100 scale where higher scores indicate better outcomes. (Final scores are normalized to a mean of 50 and standard deviation of 10.)
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm
Measure Participants	482	477
Baseline	34	34
4 Months	55	55
12 Months	55	55
24 Months	55	55
36 Months	55	55

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.82
	Comments	Baseline
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.48
	Comments	4 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.69
	Comments	12 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.63
	Comments	24 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.90
	Comments	36 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

56. Secondary Outcome

Title	H01:SF-36 Social Functioning Subscale
Description	These 2 items assess the limitations on social activities with others. Response choices range from "Extremely" or "All of the time" (1) to "Not at all" or "None of the time" (5). Item values are summed and then transformed to a 0-100 scale where higher scores indicate better social functioning. (Final scores are normalized to a mean of 50 and standard deviation of 10.)
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	601	588
Baseline	41.8 (12.0)	42.1 (12.0)
4 Months	47.0 (11.1)	45.8 (11.3)
12 Months	48.7 (10.4)	46.1 (11.7)
24 Months	48.3 (9.9)	46.1 (11.1)
36 Months	47.8 (10.3)	47.1 (10.2)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.039
	Comments	4 months
	Method	Chi-squared
	Comments	H01 P-values were based on the Chi-Square test applied to maximum likelihood estimates derived from an adjusted mixed model.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.002
	Comments	12 months
	Method	Chi-squared
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.008
	Comments	24 months
	Method	Chi-squared
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.31
	Comments	36 months
	Method	Chi-squared
	Comments

57. Secondary Outcome

Title	H02: SF-36 Social Functioning Subscale
Description	These 2 items assess the limitations on social activities with others. Response choices range from "Extremely" or "All of the time" (1) to "Not at all" or "None of the time" (5). Item values are summed and then transformed to a 0-100 scale where higher scores indicate better social functioning. (Final scores are normalized to a mean of 50 and standard deviation of 10.)
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm
Measure Participants	490	485
Baseline	41	35
4 Months	52	52
12 Months	52	52
24 Months	52	52
36 Months	52	52

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.36
	Comments	Baseline
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.87
	Comments	4 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.17
	Comments	12 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.12
	Comments	24 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.79
	Comments	36 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

58. Secondary Outcome

Title	H01:SF-36 Vitality Subscale
Description	These 4 items assess energy level and fatigue. Response choices range from "All of the time" (1) to "None of the time" (6). Item values are summed and then transformed to a 0-100 scale where higher scores indicate better vitality. (Final scores are normalized to a mean of 50 and standard deviation of 10.)
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	598	586
Baseline	46.4 (10.3)	47.5 (10.9)
4 Months	51.6 (9.8)	50.5 (10.5)
12 Months	52.2 (10.1)	49.9 (10.9)
24 Months	51.9 (9.9)	49.4 (10.5)
36 Months	51.4 (10.0)	50.6 (10.4)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments	4 months
	Method	Chi-squared
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments	12 months
	Method	Chi-squared
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments	24 months
	Method	Chi-squared
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.024
	Comments	36 months
	Method	Chi-squared
	Comments

59. Secondary Outcome

Title	H02: SF-36 Vitality Subscale
Description	These 4 items assess energy level and fatigue. Response choices range from "All of the time" (1) to "None of the time" (6). Item values are summed and then transformed to a 0-100 scale where higher scores indicate better vitality. (Final scores are normalized to a mean of 50 and standard deviation of 10.)
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm
Measure Participants	489	480
Baseline	44	44
4 Months	51	51
12 Months	53	51
24 Months	51	51
36 Months	51	51

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.31
	Comments	Baseline
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.42
	Comments	4 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.66
	Comments	12 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.32
	Comments	24 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.43
	Comments	36 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

60. Secondary Outcome

Title	H01:SF-12 Physical Component Summary (PCS) Scale
Description	Twelve items that reflect both physical and mental health are selected from the SF-36 subscales and combined according to an algebraic formula using published weights and constants: (a) First, the items are coded so that a higher value indicates better health; (b) then indicator variables (1/0) are created for the item response choice categories; (c) next, the 35 indicator variables are weighted using "physical" regression weights from the general US population and summed to produce the PCS-12 score; and (d) finally, a normalized score (with a mean of 50 and standard deviation of 10) is obtained by adding the "physical" constant from the scoring table to the sum of the 35 products.
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	534	530
Baseline	37.8 (6.1)	38.4 (5.7)
4 Months	40.2 (5.9)	39.9 (5.8)
12 Months	41.0 (5.3)	40.0 (6.0)
24 Months	41.3 (5.7)	40.9 (5.8)
36 Months	40.8 (5.5)	41.3 (5.8)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.051
	Comments	4 months
	Method	Chi-squared
	Comments	H01 P-values were based on the Chi-Square test applied to maximum likelihood estimates derived from an adjusted mixed model.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.003
	Comments	12 months
	Method	Chi-squared
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.065
	Comments	24 months
	Method	Chi-squared
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.83
	Comments	36 months
	Method	Chi-squared
	Comments

61. Secondary Outcome

Title	H02: SF-12 Physical Component Summary (PCS) Scale
Description	Twelve items that reflect both physical and mental health are selected from the SF-36 subscales and combined according to an algebraic formula using published weights and constants: (a) First, the items are coded so that a higher value indicates better health; (b) then indicator variables (1/0) are created for the item response choice categories; (c) next, the 35 indicator variables are weighted using "physical" regression weights from the general US population and summed to produce the PCS-12 score; and (d) finally, a normalized score (with a mean of 50 and standard deviation of 10) is obtained by adding the "physical" constant from the scoring table to the sum of the 35 products.
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm
Measure Participants	433	426
Baseline	37	37
4 Months	40	40
12 Months	41	41
24 Months	41	41
36 Months	40	41

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.71
	Comments	Baseline
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.57
	Comments	4 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.15
	Comments	12 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.64
	Comments	24 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.07
	Comments	36 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

62. Secondary Outcome

Title	H01: SF-12 Mental Component Summary (MCS) Scale
Description	Twelve items that reflect both physical and mental health are selected from the SF-36 subscales and combined according to an algebraic formula using published weights and constants: (a) First, the items are coded so that a higher value indicates better health; (b) then indicator variables (1/0) are created for the item response choice categories; (c) next, the 35 indicator variables are weighted using "mental" regression weights from the general US population and summed to produce the MCS-12 score; and (d) finally, a normalized score (with a mean of 50 and standard deviation of 10) is obtained by adding the "mental" constant from the scoring table to the sum of the 35 products.
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	534	530
Baseline	44.6 (12.6)	45.5 (13.0)
4 Months	50.5 (11.8)	49.2 (12.3)
12 Months	51.8 (12.1)	50.3 (12.6)
24 Months	51.6 (11.1)	49.7 (12.6)
36 Months	51.6 (11.4)	50.9 (11.9)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.004
	Comments	4 months
	Method	Chi-squared
	Comments	H01 P-values were based on the Chi-Square test applied to maximum likelihood estimates derived from an adjusted mixed model.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.011
	Comments	12 months
	Method	Chi-squared
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.007
	Comments	24 months
	Method	Chi-squared
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.044
	Comments	36 months
	Method	Chi-squared
	Comments

63. Secondary Outcome

Title	H02: SF-12 Mental Component Summary (MCS) Scale
Description	Twelve items that reflect both physical and mental health are selected from the SF-36 subscales and combined according to an algebraic formula using published weights and constants: (a) First, the items are coded so that a higher value indicates better health; (b) then indicator variables (1/0) are created for the item response choice categories; (c) next, the 35 indicator variables are weighted using "mental" regression weights from the general US population and summed to produce the MCS-12 score; and (d) finally, a normalized score (with a mean of 50 and standard deviation of 10) is obtained by adding the "mental" constant from the scoring table to the sum of the 35 products.
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm
Measure Participants	433	426
Baseline	42	41
4 Months	54	55
12 Months	57	54
24 Months	56	55
36 Months	56	56

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.74
	Comments	Baseline
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.87
	Comments	4 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.03
	Comments	12 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.60
	Comments	24 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.87
	Comments	36 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

64. Secondary Outcome

Title	H01: KCCQ Physical Limitation Scale
Description	Kansas City Cardiomyopathy Questionnaire (KCCQ)Physical Limitation Scale: These 6 items assess ability to perform various activities of daily living. Response choices range from "Extremely limited" (1) to "Not at all limited" (5). Mean scores are transformed to a 0-100 scale with high scores representing better outcomes. .
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	597	585
Baseline	64.2 (24.7)	64.7 (26.1)
4 Months	75.2 (23.6)	73.1 (23.6)
12 Months	77.8 (23.0)	73.4 (24.3)
24 Months	76.6 (23.1)	73.1 (25.4)
36 Months	76.8 (22.0)	74.9 (22.4)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.050
	Comments	4 months
	Method	Chi-squared
	Comments	H01 P-values were based on the Chi-Square test applied to maximum likelihood estimates derived from an adjusted mixed model.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.003
	Comments	12 months
	Method	Chi-squared
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments	24 months
Statistical Test of Hypothesis	p-Value	0.049
	Comments
	Method	Chi-squared
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.097
	Comments	36 months
	Method	Chi-squared
	Comments

65. Secondary Outcome

Title	H02: KCCQ Physical Limitation Scale
Description	These 6 items assess ability to perform various activities of daily living. Response choices range from "Extremely limited" (1) to "Not at all limited" (5). Mean scores are transformed to a 0-100 scale with high scores representing better outcomes.
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm
Measure Participants	484	480
Baseline	63	63
4 Months	83	83
12 Months	84	88
24 Months	88	85
36 Months	88	88

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.40
	Comments	Baseline
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.13
	Comments	4 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.86
	Comments	12 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.89
	Comments	24 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.87
	Comments	36 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

66. Secondary Outcome

Title	H01: KCCQ Symptom Stability
Description	This item assesses changes in shortness of breath or fatigue over the past 2 weeks. Response choices range from "Much worse" (1) to "Much better" (5). Item score is transformed to a 0-100 scale with a high score representing a better outcome. .
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	604	590
Baseline	53.3 (23.3)	55.5 (23.8)
4 Months	58.6 (20.5)	55.7 (19.1)
12 Months	52.8 (15.7)	51.1 (17.4)
24 Months	51.7 (14.5)	49.3 (15.5)
36 Months	50.7 (14.4)	50.8 (14.2)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.005
	Comments	4 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.023
	Comments	12 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.009
	Comments	24 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.26
	Comments	36 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

67. Secondary Outcome

Title	H02: KCCQ Symptom Stability
Description	This item assesses changes in shortness of breath or fatigue over the past 2 weeks. Response choices range from "Much worse" (1) to "Much better" (5). Item score is transformed to a 0-100 scale with a high score representing a better outcome.
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm
Measure Participants	494	492
Baseline	50	50
4 Months	50	50
12 Months	50	50
24 Months	50	50
36 Months	50	50

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.38
	Comments	Baseline
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.45
	Comments	4 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.62
	Comments	12 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.82
	Comments	24 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.94
	Comments	36 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

68. Secondary Outcome

Title	H01: KCCQ Symptom Frequency
Description	These 4 items assess how many times the patient has been bothered by shortness of breath, fatigue, and ankle swelling over the past 2 weeks. Response choices vary, but they range from "Every morning" or "Every night" or "All of the time" (1) to "Never over the past 2 weeks" (either 5 or 7). Mean scores are transformed to a 0-100 scale with high scores representing better outcomes. .
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	606	592
Baseline	70.5 (24.6)	71.5 (25.7)
4 Months	79.8 (21.6)	79.1 (21.8)
12 Months	82.4 (22.2)	79.2 (23.5)
24 Months	82.2 (20.9)	79.3 (23.3)
36 Months	81.7 (22.7)	80.4 (22.4)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.205
	Comments	4 months
	Method	Chi-squared
	Comments	H01 P-values were based on the Chi-Square test applied to maximum likelihood estimates derived from an adjusted mixed model.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.017
	Comments	12 months
	Method	Chi-squared
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.028
	Comments	24 months
	Method	Chi-squared
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.123
	Comments	36 months
	Method	Chi-squared
	Comments

69. Secondary Outcome

Title	H02: KCCQ Symptom Frequency
Description	These 4 items assess how many times the patient has been bothered by shortness of breath, fatigue, and ankle swelling over the past 2 weeks. Response choices vary, but they range from "Every morning" or "Every night" or "All of the time" (1) to "Never over the past 2 weeks" (either 5 or 7). Mean scores are transformed to a 0-100 scale with high scores representing better outcomes.
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm
Measure Participants	493	491
Baseline	67	71
4 Months	83	88
12 Months	90	90
24 Months	92	92
36 Months	92	92

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.19
	Comments	Baseline
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.07
	Comments	4 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.94
	Comments	12 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.67
	Comments	24 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.44
	Comments	36 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

70. Secondary Outcome

Title	H01: KCCQ Symptom Burden
Description	These 3 items assess how much the patient has been bothered by shortness of breath, fatigue, and ankle swelling over the past 2 weeks. Response choices range from "extremely bothersome" (1) to "Not at all bothersome" (5). Mean scores are transformed to a 0-100 scale with high scores representing better outcomes.
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	606	591
Baseline	72.6 (22.5)	73.4 (24.4)
4 Months	81.4 (20.4)	79.6 (21.0)
12 Months	83.7 (20.6)	79.8 (22.5)
24 Months	83.3 (20.2)	80.0 (23.1)
36 Months	83.1 (21.2)	80.7 (22.4)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.050
	Comments	4 months
	Method	Chi-squared
	Comments	P-values were based on the Chi-Square test applied to maximum likelihood estimates derived from an adjusted mixed model.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.006
	Comments	12 months
	Method	Chi-squared
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.039
	Comments	24 months
	Method	Chi-squared
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.074
	Comments	36 months
	Method	Chi-squared
	Comments

71. Secondary Outcome

Title	H02: KCCQ Symptom Burden
Description	These 3 items assess how much the patient has been bothered by shortness of breath, fatigue, and ankle swelling over the past 2 weeks. Response choices range from "extremely bothersome" (1) to "Not at all bothersome" (5). Mean scores are transformed to a 0-100 scale with high scores representing better outcomes.
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm
Measure Participants	494	492
Baseline	67	75
4 Months	83	83
12 Months	92	92
24 Months	92	92
36 Months	92	92

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.23
	Comments	Baseline
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.43
	Comments	4 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.35
	Comments	12 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.90
	Comments	24 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.48
	Comments	36 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

72. Secondary Outcome

Title	H01: KCCQ Total Symptoms
Description	This score represents the mean of the Symptom Frequency and Symptom Burden scores. Mean scores are transformed to a 0-100 scale with high scores representing better outcomes. .
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	606	592
Baseline	71.7 (22.5)	72.6 (24.2)
4 Months	80.8 (20.0)	79.5 (20.5)
12 Months	83.2 (20.5)	79.6 (22.1)
24 Months	82.9 (19.8)	79.8 (22.6)
36 Months	82.5 (21.3)	80.7 (21.7)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.085
	Comments	4 months
	Method	Chi-squared
	Comments	H01 P-values were based on the Chi-Square test applied to maximum likelihood estimates derived from an adjusted mixed model.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.007
	Comments
	Method	Chi-squared
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.026
	Comments	24 months
	Method	Chi-squared
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.085
	Comments	36 months
	Method	Chi-squared
	Comments

73. Secondary Outcome

Title	H02: KCCQ Total Symptoms
Description	This score represents the mean of the Symptom Frequency and Symptom Burden scores. Mean scores are transformed to a 0-100 scale with high scores representing better outcomes.
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm
Measure Participants	494	492
Baseline	68	71
4 Months	84	88
12 Months	90	88
24 Months	90	90
36 Months	90	92

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.18
	Comments	Baseline
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.17
	Comments	4 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.59
	Comments	12 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.78
	Comments	24 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	H01: Medication
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.48
	Comments	36 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

74. Secondary Outcome

Title	H01: KCCQ Quality-of-Life Scale
Description	These 3 items assess the effect of heart failure on the patient's enjoyment of life. Response choices range from 1 (worst state) to 5 (best state). Mean scores are transformed to a 0-100 scale with high scores representing better outcomes. .
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	606	591
Baseline	47.9 (25.0)	50.1 (27.0)
4 Months	68.7 (24.5)	63.3 (25.6)
12 Months	72.9 (23.5)	65.6 (25.8)
24 Months	71.9 (22.6)	66.9 (26.0)
36 Months	71.2 (23.3)	69.1 (24.8)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments	4 months
	Method	Chi-squared
	Comments	H01 P-values were based on the Chi-Square test applied to maximum likelihood estimates derived from an adjusted mixed model.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments	12 month
	Method	Chi-squared
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments	24 months
	Method	Chi-squared
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.018
	Comments	36 months
	Method	Chi-squared
	Comments

75. Secondary Outcome

Title	H02: KCCQ Quality-of-Life Scale
Description	These 3 items assess the effect of heart failure on the patient's enjoyment of life. Response choices range from 1 (worst state) to 5 (best state). Mean scores are transformed to a 0-100 scale with high scores representing better outcomes.
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm
Measure Participants	493	490
Baseline	42	33
4 Months	75	75
12 Months	75	75
24 Months	75	75
36 Months	75	83

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.70
	Comments	Baseline
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.47
	Comments	4 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.87
	Comments	12 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.84
	Comments	24 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.82
	Comments	36 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

76. Secondary Outcome

Title	H01: KCCQ Social Limitation
Description	These 4 items assess how much heart failure has affected the patient's lifestyle. Response choices range from "Severely limited" (1) to "Did not limit at all" (5). Mean scores are transformed to a 0-100 scale with high scores representing better outcomes. .
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	570	554
Baseline	56.4 (29.9)	57.3 (29.7)
4 Months	72.3 (27.4)	69.0 (27.0)
12 Months	76.4 (26.0)	69.5 (28.4)
24 Months	75.4 (25.9)	71.0 (28.8)
36 Months	75.4 (27.0)	72.8 (26.8)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.023
	Comments	4 months
	Method	Chi-squared
	Comments	H01 P-values were based on the Chi-Square test applied to maximum likelihood estimates derived from an adjusted mixed model.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.001
	Comments	12 months
	Method	Chi-squared
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.077
	Comments	24 months
	Method	Chi-squared
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.170
	Comments	36 months
	Method	Chi-squared
	Comments

77. Secondary Outcome

Title	H02: KCCQ Social Limitation
Description	These 4 items assess how much heart failure has affected the patient's lifestyle. Response choices range from "Severely limited" (1) to "Did not limit at all" (5). Mean scores are transformed to a 0-100 scale with high scores representing better outcomes.
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm
Measure Participants	465	467
Baseline	44	44
4 Months	75	75
12 Months	81	83
24 Months	81	86
36 Months	83	83

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.63
	Comments	Baseline
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.29
	Comments	4 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.68
	Comments	12 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.25
	Comments	24 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.68
	Comments	36 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

78. Secondary Outcome

Title	H01: KCCQ Clinical Summary Score
Description	This score represents the mean of the Physical Limitation and Total Symptom scores. Mean scores are transformed to a 0-100 scale with high scores representing better outcomes. .
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	607	592
Baseline	68.2 (21.8)	68.8 (23.1)
4 Months	78.2 (20.0)	76.4 (20.4)
12 Months	80.6 (20.3)	76.4 (21.9)
24 Months	80.1 (19.5)	76.6 (22.6)
36 Months	79.9 (20.2)	78.0 (20.5)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.033
	Comments	4 months
	Method	Chi-squared
	Comments	H01 P-values were based on the Chi-Square test applied to maximum likelihood estimates derived from an adjusted mixed model.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.002
	Comments	12 months
	Method	Chi-squared
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.015
	Comments	24 months
	Method	Chi-squared
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.051
	Comments	36 months
	Method	Chi-squared
	Comments

79. Secondary Outcome

Title	H02: KCCQ Clinical Summary Score
Description	This score represents the mean of the Physical Limitation and Total Symptom scores. Mean scores are transformed to a 0-100 scale with high scores representing better outcomes.
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm
Measure Participants	496	492
Baseline	65	68
4 Months	84	84
12 Months	88	86
24 Months	88	87
36 Months	88	88

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.26
	Comments	Baseline
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.23
	Comments	4 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.66
	Comments	12 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.98
	Comments	24 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.86
	Comments	36 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

80. Secondary Outcome

Title	H01: KCCQ Overall Summary Score
Description	This score represents the mean of these 4 scores: Physical Limitation, Total Symptom, Quality of Life, and Social Limitation. Mean scores are transformed to a 0-100 scale with high scores representing better outcomes. .
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	607	592
Baseline	60.3 (22.3)	61.3 (23.2)
4 Months	74.3 (21.0)	71.2 (21.3)
12 Months	77.5 (20.4)	72.2 (22.7)
24 Months	76.9 (20.1)	72.9 (23.4)
36 Months	76.6 (20.9)	74.5 (21.4)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments	4 months
	Method	Chi-squared
	Comments	H01 P-values were based on the Chi-Square test applied to maximum likelihood estimates derived from an adjusted mixed model.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments
	Method	Chi-squared
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.006
	Comments	24 months
	Method	Chi-squared
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.037
	Comments	36 months
	Method	Chi-squared
	Comments

81. Secondary Outcome

Title	H02: KCCQ Overall Summary Score
Description	This score represents the mean of these 4 scores: Physical Limitation, Total Symptom, Quality of Life, and Social Limitation. Mean scores are transformed to a 0-100 scale with high scores representing better outcomes.
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm
Measure Participants	496	492
Baseline	53	54
4 Months	79	79
12 Months	84	82
24 Months	84	84
36 Months	85	84

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.53
	Comments	Baseline
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.26
	Comments	4 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.76
	Comments	12 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.89
	Comments	24 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.89
	Comments	36 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

82. Secondary Outcome

Title	H01: Seattle Angina Questionnaire (SAQ) Anginal Frequency Subscale
Description	These 2 items assess the frequency of chest pain over the last 4 weeks. Response choices range from "4 or more times a day" (1) to "None" (6). The mean response is transformed to a 0-100 scale where higher scores reflect less frequent angina. .
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	594	584
Baseline	74.3 (26.7)	77.0 (26.2)
4 Months	90.5 (16.9)	84.0 (23.2)
12 Months	90.6 (16.5)	84.0 (22.4)
24 Months	90.5 (17.2)	86.5 (19.7)
36 Months	89.8 (17.5)	88.5 (19.0)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments	4 months
	Method	Chi-squared
	Comments	H01 P-values were based on the Chi-Square test applied to maximum likelihood estimates derived from an adjusted mixed model.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments	12 months
	Method	Chi-squared
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments	24 months
	Method	Chi-squared
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.010
	Comments	36 months
	Method	Chi-squared
	Comments

83. Secondary Outcome

Title	H02: Seattle Angina Questionnaire (SAQ) Anginal Frequency Subscale
Description	These 2 items assess the frequency of chest pain over the last 4 weeks. Response choices range from "4 or more times a day" (1) to "None" (6). The mean response is transformed to a 0-100 scale where higher scores reflect less frequent angina.
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm
Measure Participants	488	482
Baseline	70	80
4 Months	100	100
12 Months	100	100
24 Months	100	100
36 Months	100	100

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.01
	Comments	Baseline
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.74
	Comments	4 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.77
	Comments	12 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.46
	Comments	24 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.27
	Comments	36 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

84. Secondary Outcome

Title	H01: Seattle Angina Questionnaire (SAQ) Anginal Stability Subscale
Description	This item assesses the change in chest pain over the last 4 weeks. Response choices range from "Much more often" (1) to "None" (6). The mean response is transformed to a 0-100 scale where 50 represents no change and a higher score indicates less angina. .
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	575	565
Baseline	56.0 (27.1)	57.8 (25.0)
4 Months	58.3 (20.3)	55.8 (20.6)
12 Months	55.4 (17.3)	53.3 (17.6)
24 Months	52.9 (14.9)	52.9 (17.4)
36 Months	53.9 (16.9)	53.6 (15.5)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.029
	Comments	4 months
	Method	Chi-squared
	Comments	H01 P-values were based on the Chi-Square test applied to maximum likelihood estimates derived from an adjusted mixed model.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.042
	Comments	12 months
	Method	Chi-squared
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.30
	Comments	24 months
	Method	Chi-squared
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.20
	Comments	36 months
	Method	Chi-squared
	Comments

85. Secondary Outcome

Title	H02: Seattle Angina Questionnaire (SAQ) Anginal Stability Subscale
Description	This item assesses the change in chest pain over the last 4 weeks. Response choices range from "Much more often" (1) to "None" (6). The mean response is transformed to a 0-100 scale where 50 represents no change and a higher score indicates less angina.
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm
Measure Participants	477	462
Baseline	50	50
4 Months	50	50
12 Months	50	50
24 Months	50	50
36 Months	50	50

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.98
	Comments	Baseline
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.16
	Comments	4 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.88
	Comments	12 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.95
	Comments	24 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.48
	Comments	36 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

86. Secondary Outcome

Title	H01:Seattle Angina Questionnaire (SAQ) Quality-of-Life Subscale
Description	These 3 items measure the patient's general satisfaction with life. Response choices range from 1 (least enjoyment) to 5 (high satisfaction). The mean score is transformed to a 0-100 scale where higher scores reflect better outcomes. .
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	585	574
Baseline	53.6 (25.9)	57.6 (26.6)
4 Months	74.5 (22.1)	67.5 (24.4)
12 Months	75.8 (21.2)	69.1 (24.0)
24 Months	75.5 (21.5)	68.7 (24.9)
36 Months	75.3 (22.1)	72.9 (22.2)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments	4 months
	Method	Chi-squared
	Comments	H01 P-values were based on the Chi-Square test applied to maximum likelihood estimates derived from an adjusted mixed model.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments	12 months
	Method	Chi-squared
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments	24 months
	Method	Chi-squared
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.001
	Comments	36 months
	Method	Chi-squared
	Comments

87. Secondary Outcome

Title	H02: Seattle Angina Questionnaire (SAQ) Quality-of-Life Subscale
Description	These 3 items measure the patient's general satisfaction with life. Response choices range from 1 (least enjoyment) to 5 (high satisfaction). The mean score is transformed to a 0-100 scale where higher scores reflect better outcomes.
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm
Measure Participants	484	478
Baseline	42	42
4 Months	83	83
12 Months	83	83
24 Months	83	83
36 Months	83	83

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.86
	Comments	Baseline
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.39
	Comments	4 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.65
	Comments	12 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.15
	Comments	24 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.68
	Comments	36 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

88. Secondary Outcome

Title	H01: EQ-5D Visual Analog Scale
Description	Euro QoL 5 Dimensions Quality of Life Instrument (EQ-5D): This 0-100 scale records the patient's self-rated health on a vertical scale where 0 = worst imaginable health and 100 = perfect health. .
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	593	585
Baseline	56.7 (19.0)	59.5 (18.8)
4 Months	68.5 (18.1)	65.4 (17.7)
12 Months	69.2 (17.9)	65.4 (18.5)
24 Months	68.6 (17.8)	65.9 (18.4)
36 Months	69.0 (17.9)	67.1 (17.4)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments	4 months
	Method	Chi-squared
	Comments	H01 P-values were based on the Chi-Square test applied to maximum likelihood estimates derived from an adjusted mixed model.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments	12 months
	Method	Chi-squared
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.001
	Comments	24 months
	Method	Chi-squared
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.001
	Comments
	Method	Chi-squared
	Comments

89. Secondary Outcome

Title	H02: EQ-5D Visual Analog Scale
Description	This 0-100 scale records the patient's self-rated health on a vertical scale where 0 = worst imaginable health and 100 = perfect health.
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm
Measure Participants	488	487
Baseline	50	50
4 Months	70	70
12 Months	72	70
24 Months	70	70
36 Months	70	70

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.96
	Comments	Baseline
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.53
	Comments	4 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.37
	Comments	12 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.78
	Comments	24 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.21
	Comments	36 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

90. Secondary Outcome

Title	H01: EQ-5D Health Status Index Score
Description	This 5-item scale describes a patient's health in terms of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Choices for each dimension are "No problems" (1), "Moderate problems" (2), or "Extreme problems" (3). A scoring algorithm with utility weights is then applied to these 5 items to generate index scores ranging from -0.11 (i.e., 33333) to 1.0 (i.e., 11111) on a scale where 0.0 = death and 1.0 = perfect health. These scores were multiplied by 100 to produce a scale from -11 to 100 that more closely resembles the Visual Analog Scale. .
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	584	570
Baseline	69.3 (25.8)	72.3 (24.4)
4 Months	78.9 (24.5)	77.4 (22.6)
12 Months	80.5 (22.3)	77.6 (24.0)
24 Months	79.6 (24.6)	78.1 (25.9)
36 Months	81.4 (23.4)	81.5 (21.6)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.007
	Comments	4 months
	Method	Chi-squared
	Comments	H01 P-values were based on the Chi-Square test applied to maximum likelihood estimates derived from an adjusted mixed model.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.003
	Comments	12 months
	Method	Chi-squared
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.023
	Comments	24 months
	Method	Chi-squared
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.060
	Comments	36 months
	Method	Chi-squared
	Comments

91. Secondary Outcome

Title	H02: EQ-5D Health Status Index Score
Description	This 5-item scale describes a patient's health in terms of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Choices for each dimension are "No problems" (1), "Moderate problems" (2), or "Extreme problems" (3). A scoring algorithm with utility weights is then applied to these 5 items to generate index scores ranging from -0.11 (i.e., 33333) to 1.0 (i.e., 11111) on a scale where 0.0 = death and 1.0 = perfect health. (These scores can be multiplied by 100 to produce a scale from -11 to 100 that more closely resembles the Visual Analog Scale.)
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm
Measure Participants	475	477
Baseline	69	69
4 Months	85	85
12 Months	85	85
24 Months	85	85
36 Months	85	85

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.31
	Comments	Baseline
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.43
	Comments	4 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.57
	Comments	12 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.95
	Comments	24 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.38
	Comments	36 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

92. Secondary Outcome

Title	H01: Percentage of Patients With a Score of >= 16 on the Center for Epidemiological Studies Depression (CES-D) Scale
Description	These 20 items assess depressive symptomatology, and responses choices range from "Rarely or none of the time" (0) to "Most or all of the time" (3). Scale scores can therefore range from 0 to 60, although scores greater than or equal to 16 are considered high. .
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	595	583
Baseline	42.9 7.1%	43.4 8.1%
4 Months	26.6 4.4%	27.5 5.1%
12 Months	25.0 4.2%	26.9 5%
24 Months	24.1 4%	31.1 5.8%
36 Months	22.4 3.7%	29.5 5.5%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.86
	Comments	Baseline
	Method	Chi-squared
	Comments	All P-values were based on the Likelihood Ratio Chi-Square test.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.78
	Comments	4 months
	Method	Chi-squared
	Comments	All P-values were based on the Likelihood Ratio Chi-Square test.

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.55
	Comments	12 months
	Method	Chi-squared
	Comments	All P-values were based on the Likelihood Ratio Chi-Square test.

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.027
	Comments	24 months
	Method	Chi-squared
	Comments	All P-values were based on the Likelihood Ratio Chi-Square test.

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.031
	Comments	36 months
	Method	Chi-squared
	Comments	All P-values were based on the Likelihood Ratio Chi-Square test.

93. Secondary Outcome

Title	H02: Percentage of Patients With a Score of >= 16 on the Center for Epidemiological Studies Depression (CES-D) Scale
Description	These 20 items assess depressive symptomatology, and responses choices range from "Rarely or none of the time" (0) to "Most or all of the time" (3). Scale scores can therefore range from 0 to 60, although scores greater than or equal to 16 are considered high.
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm
Measure Participants	496	495
Baseline	50.5 8.4%	53.2 10%
4 Months	29.6 4.9%	27.0 5.1%
12 Months	24.4 4.1%	27.0 5.1%
24 Months	28.1 4.7%	24.3 4.6%
36 Months	20.8 3.5%	24.8 4.6%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.40
	Comments	Baseline
	Method	Chi-squared
	Comments	All P-values were based on the Likelihood Ratio Chi-Square test.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.42
	Comments	4 months
	Method	Chi-squared
	Comments	All P-values were based on the Likelihood Ratio Chi-Square test.

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.41
	Comments	12 months
	Method	Chi-squared
	Comments	All P-values were based on the Likelihood Ratio Chi-Square test.

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.25
	Comments	24 months
	Method	Chi-squared
	Comments	All P-values were based on the Likelihood Ratio Chi-Square test.

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.25
	Comments	36 months
	Method	Chi-squared
	Comments	All P-values were based on the Likelihood Ratio Chi-Square test.

94. Secondary Outcome

Title	H01: Cardiac Self-Efficacy (CSE) Maintain Functioning Subscale
Description	These 5 items assess patients' ability to maintain their usual social, family, and physical activities. Response choices range from "Not at all confident" (1) to "Completely confident" (5). The mean score is transformed to a 0-100 scale where higher scores reflect more confidence. .
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	596	581
Baseline	46.8 (24.3)	49.3 (24.9)
4 Months	56.0 (25.0)	53.8 (24.8)
12 Months	56.7 (25.9)	53.9 (26.7)
24 Months	55.3 (25.2)	53.3 (26.4)
36 Months	56.2 (26.0)	54.9 (26.7)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.002
	Comments	4 months
	Method	Chi-squared
	Comments	H01 P-values were based on the Chi-Square test applied to maximum likelihood estimates derived from an adjusted mixed model.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.007
	Comments	12 months
	Method	Chi-squared
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.049
	Comments	24 months
	Method	Chi-squared
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.038
	Comments	36 months
	Method	Chi-squared
	Comments

95. Secondary Outcome

Title	H02: Cardiac Self-Efficacy (CSE) Maintain Functioning Subscale
Description	These 5 items assess patients' ability to maintain their usual social, family, and physical activities. Response choices range from "Not at all confident" (1) to "Completely confident" (5). The mean score is transformed to a 0-100 scale where higher scores reflect more confidence.
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm
Measure Participants	487	481
Baseline	45	45
4 Months	61	63
12 Months	65	64
24 Months	63	65
36 Months	58	63

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.40
	Comments	Baseline
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.37
	Comments	4 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.98
	Comments	12 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.15
	Comments	24 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.04
	Comments	36 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

96. Secondary Outcome

Title	H01: Cardiac Self-Efficacy (CSE) Control Symptoms Subscale
Description	These 8 items assess patients' ability to control symptoms such as chest pain and breathlessness by taking their medications and adjusting their activity levels. Response choices range from "Not at all confident" (1) to "Completely confident" (5). The mean score is transformed to a 0-100 scale where higher scores reflect more confidence. .
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	599	583
Baseline	62.9 (22.5)	64.8 (21.2)
4 Months	69.2 (20.6)	68.7 (20.5)
12 Months	68.7 (20.3)	67.4 (21.8)
24 Months	68.3 (20.4)	66.2 (21.3)
36 Months	69.7 (21.0)	68.3 (21.1)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.036
	Comments	4 months
	Method	Chi-squared
	Comments	H01 P-values were based on the Chi-Square test applied to maximum likelihood estimates derived from an adjusted mixed model.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.043
	Comments	12 months
	Method	Chi-squared
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.018
	Comments	24 months
	Method	Chi-squared
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.037
	Comments	36 months
	Method	Chi-squared
	Comments

97. Secondary Outcome

Title	H02: Cardiac Self-Efficacy (CSE) Control Symptoms Subscale
Description	These 8 items assess patients' ability to control symptoms such as chest pain and breathlessness by taking their medications and adjusting their activity levels. Response choices range from "Not at all confident" (1) to "Completely confident" (5). The mean score is transformed to a 0-100 scale where higher scores reflect more confidence.
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm
Measure Participants	487	482
Baseline	63	63
4 Months	75	75
12 Months	75	75
24 Months	75	75
36 Months	75	75

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.75
	Comments	Baseline
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.72
	Comments	4 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.77
	Comments	12 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.52
	Comments	24 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.12
	Comments	36 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

98. Secondary Outcome

Title	H01: General Health Rating Scale
Description	This single item asks patients to describe their health status over the past month on a scale from 0 to 100, where 0 = death and 100 = excellent health. .
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	Total H01: Medication + CABG	H01: Medication
Arm/Group Description	H01 patients were randomized to medical therapy plus CABG. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm.	H01 patients were randomized to medical therapy alone. Throughout the trial follow-up period, the use of guideline-recommended medications and devices for the treatment of heart failure and CAD was strongly emphasized for all patients in this treatment arm.
Measure Participants	579	554
Baseline	56.0 (19.4)	57.6 (19.0)
4 Months	67.3 (19.1)	64.0 (18.1)
12 Months	68.7 (18.7)	63.7 (19.1)
24 Months	68.1 (19.2)	65.0 (19.6)
36 Months	69.1 (31.6)	67.1 (33.7)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.0002
	Comments	4 months
	Method	Chi-squared
	Comments	H01 P-values were based on the Chi-Square test applied to maximum likelihood estimates derived from an adjusted mixed model.

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.0001
	Comments	12 months
	Method	Chi-squared
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.009
	Comments	24 months
	Method	Chi-squared
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.32
	Comments	36 months
	Method	Chi-squared
	Comments

99. Secondary Outcome

Title	H02: General Health Rating Scale
Description	This single item asks patients to describe their health status over the past month on a scale from 0 to 100, where 0 = death and 100 = excellent health.
Time Frame	From enrollment to 3-year follow-up

Outcome Measure Data

Analysis Population Description

Only patients with questionnaire data were analyzed.

Arm/Group Title	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	50% of H02 patients were randomized to this medical therapy plus CABG arm. In addition to the guideline-recommended medications, coronary artery bypass graft (CABG) surgery was to be performed for patients randomized to this treatment arm. This group does not include those 76 patients who belong to both H01 and H02.	50% of H02 patients were randomized to this medical therapy plus CABG plus SVR arm. In addition to the guideline-recommended medications, both the coronary artery bypass graft (CABG) surgery and the surgical ventricular reconstruction (SVR) were to be performed for patients randomized to this treatment arm
Measure Participants	466	458
Baseline	50	50
4 Months	70	70
12 Months	70	70
24 Months	70	70
36 Months	70	70

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.60
	Comments	Baseline
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.14
	Comments	4 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.57
	Comments	12 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.15
	Comments	24 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.84
	Comments	36 months
	Method	Wilcoxon (Mann-Whitney)
	Comments

100. Secondary Outcome

Title	H01: Cost of Care
Description	Hospital costs and physician fees for US patients
Time Frame	index hospital admission

Outcome Measure Data

Analysis Population Description

US patients with hospital bills

Arm/Group Title	H01: Medication + CABG	H01: Medication
Arm/Group Description	Coronary artery bypass graft surgery (CABG) plus Medication to treat coronary artery disease CABG surgery plus MED (medication): CABG plus standard medication management for Coronary Artery Disease	Medical therapy alone to treat Coronary Artery Disease Active Medication Alone: Standard medication for coronary artery disease and heart failure management.
Measure Participants	66	54
Hospital Costs	50,032 (41,622)	8,315 (19,719)
Physician Fees	5,405 (2,377)	408 (819)
Total Index Cost	55,437 (43,460)	8,723 (20,506)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.0001
	Comments	Hospital costs
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.0001
	Comments	Physician fees
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.0001
	Comments	Total index cost
	Method	Wilcoxon (Mann-Whitney)
	Comments

101. Secondary Outcome

Title	H02: Cost of Care
Description	Hospital costs and physician fees for US patients
Time Frame	index hospital admission

Outcome Measure Data

Analysis Population Description

US patients with hospital bills

Arm/Group Title	H02: Medication+CABG	H02: Medication+CABG+SVR
Arm/Group Description	Coronary artery bypass graft surgery (CABG) plus Medication to treat coronary artery disease CABG surgery plus MED: CABG plus standard medication management for Coronary Artery Disease	CABG plus Medication and Surgical ventricular reconstruction (SVR) CABG plus MED and SVR: H02: the experimental arm receives active medical therapy and CABG and surgical ventricular restoration whereas the control group receives active medical therapy and CABG; for H01: the experimental arm receives active medical therapy and CABG whereas the control group receives active medical therapy alone
Measure Participants	100	96
Hospital Costs	50,939 (46,458)	64,202 (49,172)
Physician Fees	5,183 (2,306)	6,515 (2,463)
Total Index Cost	56,122 (48,552)	70,717 (51,367)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.006
	Comments	Hospital costs
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.0001
	Comments	Physician fees
	Method	Wilcoxon (Mann-Whitney)
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	H01: Medication, Total H01: Medication + CABG
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.004
	Comments	Total index cost
	Method	Wilcoxon (Mann-Whitney)
	Comments

Adverse Events

Time Frame	No "other" adverse events were collected, however serious adverse events were collected for the first 5 years of the follow up period per study protocol.
Arm/Group Title	H01: Medication		H01: Medication + CABG		H01 & H02: Medication+CABG		H02: Medication+CABG		H02: Medication+CABG+SVR
Arm/Group Description
All Cause Mortality
	H01: Medication		H01: Medication + CABG		H01 & H02: Medication+CABG		H02: Medication+CABG		H02: Medication+CABG+SVR
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	/ (NaN)		/ (NaN)		/ (NaN)		/ (NaN)		/ (NaN)
Serious Adverse Events
	H01: Medication		H01: Medication + CABG		H01 & H02: Medication+CABG		H02: Medication+CABG		H02: Medication+CABG+SVR
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	84/602 (14%)		85/534 (15.9%)		9/76 (11.8%)		31/423 (7.3%)		53/501 (10.6%)
Blood and lymphatic system disorders
HEPARIN-INDUCED THROMBOCYTOPENIA	0/602 (0%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		2/501 (0.4%)
LEUKOCYTOSIS	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
Cardiac disorders
ACUTE CORONARY SYNDROME	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
ACUTE HEART FAILURE	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
ACUTE LEFT VENTRICULAR FAILURE	2/602 (0.3%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
ACUTE MYOCARDIAL INFARCTION	1/602 (0.2%)		4/534 (0.7%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
ANGINA PECTORIS	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
ANGINAL DISCOMFORT	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
ARRHYTHMIA	6/602 (1%)		7/534 (1.3%)		0/76 (0%)		1/423 (0.2%)		4/501 (0.8%)
ASYSTOLIA	0/602 (0%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
ATRIAL FIBRILLATION	1/602 (0.2%)		1/534 (0.2%)		0/76 (0%)		2/423 (0.5%)		0/501 (0%)
CARDIAC ARREST	5/602 (0.8%)		5/534 (0.9%)		0/76 (0%)		0/423 (0%)		2/501 (0.4%)
CARDIAC ARRHYTHMIA	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		1/423 (0.2%)		0/501 (0%)
CARDIAC DISORDER	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
CARDIAC FAILURE	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
CARDIAC FAILURE ACUTE	0/602 (0%)		0/534 (0%)		0/76 (0%)		1/423 (0.2%)		0/501 (0%)
CARDIAC FAILURE AGGRAVATED	2/602 (0.3%)		0/534 (0%)		0/76 (0%)		1/423 (0.2%)		1/501 (0.2%)
CARDIAC TAMPONADE	1/602 (0.2%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
CARDIAC VENTRICULAR THROMBOSIS	0/602 (0%)		0/534 (0%)		1/76 (1.3%)		0/423 (0%)		0/501 (0%)
CARDIOGENIC SHOCK	3/602 (0.5%)		3/534 (0.6%)		0/76 (0%)		2/423 (0.5%)		2/501 (0.4%)
CARDIOPULMONARY INSUFFICIENCY	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
CARDIOVASCULAR INSUFFICIENCY	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
CONGESTIVE CARDIAC FAILURE	0/602 (0%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
CONGESTIVE HEART FAILURE	3/602 (0.5%)		2/534 (0.4%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
CORONARY OCCLUSION	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
DECOMPENSATED HEART FAILURE	0/602 (0%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		2/501 (0.4%)
DECOMPENSATION CARDIAC	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		2/501 (0.4%)
END STAGE CARDIAC FAILURE	0/602 (0%)		0/534 (0%)		0/76 (0%)		2/423 (0.5%)		0/501 (0%)
HEART FAILURE	11/602 (1.8%)		6/534 (1.1%)		1/76 (1.3%)		3/423 (0.7%)		2/501 (0.4%)
INSUFFICIENCY CARDIAC	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
ISCHEMIC CARDIOMYOPATHY	1/602 (0.2%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
LEFT VENTRICULAR FAILURE	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
LOW CARDIAC OUTPUT SYNDROME	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
MALIGNANT VENTRICULAR ARRHYTHMIAS	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		1/423 (0.2%)		0/501 (0%)
MITRAL VALVE DISEASE	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
MYOCARDIAL INFARCTION	2/602 (0.3%)		3/534 (0.6%)		0/76 (0%)		2/423 (0.5%)		2/501 (0.4%)
OTHER CARDIAC	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
PAROXYSMAL ATRIAL FIBRILLATION	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
PERICARDIAL EFFUSION	0/602 (0%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		2/501 (0.4%)
PULSELESS ELECTRICAL ACTIVITY	0/602 (0%)		0/534 (0%)		0/76 (0%)		1/423 (0.2%)		0/501 (0%)
SUSTAINED VENTRICULAR TACHYCARDIA	0/602 (0%)		0/534 (0%)		1/76 (1.3%)		0/423 (0%)		0/501 (0%)
SVT	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
TACHYCARDIA	0/602 (0%)		0/534 (0%)		0/76 (0%)		1/423 (0.2%)		0/501 (0%)
UNSTABLE ANGINA	2/602 (0.3%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
VENTRICULAR ARRHYTHMIA	2/602 (0.3%)		4/534 (0.7%)		0/76 (0%)		1/423 (0.2%)		0/501 (0%)
VENTRICULAR FIBRILLATION	6/602 (1%)		3/534 (0.6%)		2/76 (2.6%)		0/423 (0%)		1/501 (0.2%)
VENTRICULAR TACHYCARDIA	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		2/501 (0.4%)
Ear and labyrinth disorders
VERTIGO	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
Endocrine disorders
HYPERTHYROIDISM	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
Gastrointestinal disorders
ASCITES	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
BOWEL ISCHEMIA	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
DIARRHEA	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
GASTRIC ULCER PERFORATED	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
GASTROINTESTINAL NECROSIS	0/602 (0%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
UPPER GASTROINTESTINAL HEMORRHAGE	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
VOMITING	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
General disorders
DEVICE LEAD ISSUE	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
EDEMA	0/602 (0%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
HERNIA	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
MULTI ORGAN FAILURE	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
MULTIORGAN FAILURE	0/602 (0%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
MULTIPLE ORGAN FAILURE	0/602 (0%)		0/534 (0%)		1/76 (1.3%)		0/423 (0%)		0/501 (0%)
SIRS	0/602 (0%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
Hepatobiliary disorders
CARDIAC CIRRHOSIS	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
GALLSTONES	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
HEPATIC INSUFFICIENCY	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
HEPATOMEGALY	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
JAUNDICE	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
Infections and infestations
ABSCESS	0/602 (0%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
BACTEREMIA	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
BRONCHITIS	2/602 (0.3%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
CMV INFECTION	0/602 (0%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
CYSTITIS	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
IMPLANT SITE INFECTION	0/602 (0%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
INFECTED SKIN ULCER	0/602 (0%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
INFECTION	0/602 (0%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		2/501 (0.4%)
MEDIASTINITIS	0/602 (0%)		4/534 (0.7%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
NECROTIZING FASCIITIS	1/602 (0.2%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
PNEUMONIA	1/602 (0.2%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
SEPSIS	1/602 (0.2%)		1/534 (0.2%)		0/76 (0%)		1/423 (0.2%)		0/501 (0%)
SEPTIC SHOCK	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
Injury, poisoning and procedural complications
CHRONIC SUBDURAL HAEMATOMA	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
POSTOPERATIVE HEMORRHAGE	0/602 (0%)		0/534 (0%)		0/76 (0%)		1/423 (0.2%)		0/501 (0%)
POSTPERICARDIOTOMY SYNDROME	0/602 (0%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
STERNAL DEHISCENCE	0/602 (0%)		2/534 (0.4%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
Investigations
BUN INCREASED	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
CREATININE INCREASED	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
Metabolism and nutrition disorders
GOUT	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
HYPERKALEMIA	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
HYPOKALEMIA	0/602 (0%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
HYPOVOLEMIA	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
VOLUME OVERLOAD	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
Musculoskeletal and connective tissue disorders
MYOPATHY	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
SCLERODERMA	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BRAIN TUMOR	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
CANCER OF LUNG	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
COLON CANCER	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
LUNG CANCER METASTATIC	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
MESOTHELIOMA MALIGNANT	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
MYELODYSPLASTIC SYNDROME	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
SQUAMOUS CELL CARCINOMA	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
Nervous system disorders
ALS	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
ANOXIC ENCEPHALOPATHY	0/602 (0%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
EMBOLIC CEREBRAL INFARCTION	0/602 (0%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
HEMORRHAGE BRAIN	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
LOSS OF CONSCIOUSNESS	0/602 (0%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
STROKE	17/602 (2.8%)		16/534 (3%)		2/76 (2.6%)		9/423 (2.1%)		10/501 (2%)
Psychiatric disorders
CONFUSION	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
Renal and urinary disorders
ACUTE RENAL FAILURE	0/602 (0%)		7/534 (1.3%)		1/76 (1.3%)		4/423 (0.9%)		9/501 (1.8%)
RENAL FAILURE	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		1/423 (0.2%)		0/501 (0%)
RENAL INSUFFICIENCY	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		1/423 (0.2%)		0/501 (0%)
Respiratory, thoracic and mediastinal disorders
ACUTE PULMONARY EDEMA	2/602 (0.3%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
ACUTE PULMONARY OEDEMA	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
ACUTE RESPIRATORY INSUFFICIENCY	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
ASPIRATION PNEUMONIA	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
CHRONIC OBSTRUCTIVE PULMONARY DISEASE	0/602 (0%)		0/534 (0%)		0/76 (0%)		1/423 (0.2%)		0/501 (0%)
DYSPNEA	0/602 (0%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
EDEMA PULMONARY	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
EPISTAXIS	0/602 (0%)		0/534 (0%)		1/76 (1.3%)		0/423 (0%)		0/501 (0%)
MEDIASTINAL HEMORRHAGE	0/602 (0%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
PLEURAL EFFUSION	1/602 (0.2%)		2/534 (0.4%)		0/76 (0%)		0/423 (0%)		2/501 (0.4%)
PULMONARY ARTERY THROMBOSIS	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
PULMONARY EDEMA	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		1/423 (0.2%)		0/501 (0%)
PULMONARY EMBOLISM	0/602 (0%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
PULMONARY EMBOLUS	0/602 (0%)		0/534 (0%)		0/76 (0%)		1/423 (0.2%)		1/501 (0.2%)
PULMONARY THROMBOEMBOLISM	1/602 (0.2%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
RESPIRATORY FAILURE	0/602 (0%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
RESPIRATORY INSUFFICIENCY	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
SHORTNESS OF BREATH	0/602 (0%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
Skin and subcutaneous tissue disorders
ANGIOEDEMA	0/602 (0%)		0/534 (0%)		0/76 (0%)		1/423 (0.2%)		0/501 (0%)
NECROSIS SKIN	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
SKIN TROPHIC ULCER	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
Surgical and medical procedures
HOSPITALIZATION NOS	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
Vascular disorders
AORTIC RUPTURE	0/602 (0%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
ARTERIAL EMBOLISM (LIMBS)	4/602 (0.7%)		3/534 (0.6%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
CLAUDICATION	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
HAEMODYNAMIC INSTABILITY	0/602 (0%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		1/501 (0.2%)
HEMODYNAMIC INSTABILITY	1/602 (0.2%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
HYPOTENSION	0/602 (0%)		0/534 (0%)		0/76 (0%)		1/423 (0.2%)		0/501 (0%)
LOW BLOOD PRESSURE	2/602 (0.3%)		0/534 (0%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
PERIPHERAL VASCULAR DISEASE	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
SUPERFICIAL PHLEBOTHROMBOSIS	0/602 (0%)		1/534 (0.2%)		0/76 (0%)		0/423 (0%)		0/501 (0%)
Other (Not Including Serious) Adverse Events
	H01: Medication		H01: Medication + CABG		H01 & H02: Medication+CABG		H02: Medication+CABG		H02: Medication+CABG+SVR
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/0 (NaN)		0/0 (NaN)		0/0 (NaN)		0/0 (NaN)		0/0 (NaN)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

The agreement is that all publications need to be reviewed and approved by the Policy and Publication Committee and the Sponsor prior to publication.